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Abstract 
 
This study compares pharmaceutical company research on new medicines in South 
Africa with the country’s burden of disease and describes the process and criteria that 
companies use to set their research priorities.  A quantitative survey of pharmaceutical 
companies shows that company research conducted from 2000 to 2003 is moderately 
associated with the country’s burden of disease estimates for 2000.  The degree of 
association is dependent on which measures of company research and burden of 
disease are compared, and which comparative statistic is used.  A qualitative analysis of 
company interviews reveals that feasibility of clinical trials, market forces, and 
environmental factors are core criteria for company research priority setting.  The burden 
of disease, although important, is not a sole criterion, and has considerable limitations. 
Furthermore, this study reveals the complex nature of health priority setting by 
pharmaceutical companies and thus can assist policy decision makers in identifying 
practical strategies to encourage research in diseases of need by pharmaceutical 
companies. 
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Definitions 
 
Burden of Disease (BoD) – A “comprehensive measure of the health status of the nation by 
assessing ill health and causes of death [and] includes fatal and non-fatal outcomes” (MRC 
2003a, 1). 
 
Clinical Trial –   “Any  investigation  in human subjects  intended to  discover or  verify the clinical, 
pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to 
identify any adverse reactions to an investigational product(s), and/or to study absorption, 
distribution, metabolism, and excretion of an investigational product(s) with the object of 
ascertaining its safety and/or efficacy” (DoH 2000, 71). 
 
Contract Research Organisation (CRO) – “A person or an organisation (commercial, academic, or 
other) contracted by the sponsor to perform one or more of a sponsor’s trial-related duties and 
functions” (DoH 2000, 71). 
 
Disability Adjusted Life Year (DALYs) – “A single measure of burden of disease, using time to 
equate death and disability, it comprises of years of life lost (YLLs) due to premature mortality 
and ‘years lived with a disability’ (YLDs), weighted according to severity of disability.  It is thus a 
summary measure of population health, combining information on death and non-fatal health 
outcomes.  It effectively measures the future stream of health years of life lost due to each 
incident case of disease or injury” (Bradshaw, et al., 2003b, 1). 
 
Investigational Product – “A pharmaceutical form of an active ingredient or placebo being tested 
or used as a reference in a clinical trial, including a product with a marketing authorisation when 
used or assembled (formulated or packaged) in a way different from the approved form, or when 
used for an unapproved indication, or when used to gain further information about an approved 
use” (DoH 2000, 73). 
 
Investigator – “A person responsible for the conduct of the clinical trial at a trial site.  If a trial is 
conducted by a team of individuals at a trial site, the investigator is the responsible leader of the 
team and may be called the Principal Investigator” (DoH 2000, 73). 
 
Participants – people who participate in either the control or intervention arm of a clinical trial 
 
Phase I – A “new drug, vaccine or medical device∗ is tested in a small group of usually healthy 
persons for the very first time…to determine the general safety, the correct dosage and possible 
negative or undesirable effects” (DoH 2002, 2). 
                                                
∗ Although the DoH definitions regarding clinical trials include medical devices, MEDICAL DEVICES ARE NOT 
INCLUDED in this study 
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 Phase II – “The new drug, vaccine or medical device is tested in a larger group (several hundred 
healthy people)…[and possibly] people with the disease being tested for…to further test the 
safety and effectiveness of the new drug, vaccine or medical device” (DoH 2002, 2). 
 
Phase III – “The new drug, vaccine or medical device is tested in a larger group (several hundred 
to a few thousand) of people who suffer from the disease/illness for which the new drug, vaccine 
or medical device is intended [to evaluate] the effectiveness and possible undesirable effects [and 
compare it] to old registered (licensed) drugs, vaccines or medical devices, or alternative 
treatment options” (DoH 2002, 3). 
 
Phase IV – “Trials after the new drug, vaccine or medical device has been registered and 
licensed for sale by the Medicines Control Council (MCC)…the drug, vaccine or medical device is 
tested in several thousand people to: 
• define its safety, effectiveness, long-term undesirable effects, 
• test the new drug, vaccine or medical device in certain high risk sectors of the population 
like children, the elderly, people with liver and kidney disease, and 
• find new uses (indications) of the new drug, vaccine or medical device” (DoH 2002, 3). 
 
Pre-Clinical Research – The study of new medicines or devices “over a long period, in the 
laboratory and in various animals to establish its initial safety and effectiveness” prior to testing or 
trials in people (DoH 2002, 2). 
 
Site - The location(s) of a clinical trial which is managed by a principal investigator 
 
Years Life Lost (YLL) – “calculated by subtracting a person’s age at death from his or her life 
expectancy in the absence of a given disease” (Gross, et al., 1999, 1882) 
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1.0 Introduction 
This study compares pharmaceutical company research on new medicines in South 
Africa with the country’s burden of disease and describes the process and criteria that 
companies use to set their research priorities. 
  
1.1 Summary of Problem 
It is unknown to what extent pharmaceutical company research in South Africa reflects 
the country’s burden of disease (hereinafter referred to as BoD), or how companies set 
their research priorities.  This is important to examine from a public health perspective 
because if private pharmaceutical industry research efforts in the country are to be 
leveraged to meet public health needs, policy makers need to first establish a baseline 
relationship between company research and the country’s health needs in order to 
identify opportunities for research.  First, the use of BoD as a measure of a country’s 
health need is a common starting point for health priority setting, with the assumption 
that there should be some alignment between priorities and needs.  This assumption 
underpins growing concerns from public health experts that pharmaceutical companies 
do not conduct research in diseases with high burdens in low- and medium-income 
countries.  However, the limits on the use of BoD as a means of quantifying health need 
and as a sole comparator for research are recognised in this report.  
 
Second, although comparing research with BoD is a first step toward identifying 
opportunities for research, the process of health research priority setting is far more 
complex.  Therefore, policy makers need to understand how companies set their 
research priorities so that practical policies to support research in diseases of need can 
be developed.  The specific processes and criteria companies use to set research 
priorities in South Africa has not been thoroughly studied.   It is important to note that 
South Africans also benefit from other global research conducted outside of the country, 
which was not captured in this study due to the difficulties in obtaining disease-specific 
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international research data.  However, this study can provide an initial platform for public 
and private industry policy makers to maximise private pharmaceutical industry research 
in South Africa to benefit public health needs. 
 
1.2 Overall Aims of the Study 
The aims of this study were to: 
• Identify the disease priorities for pharmaceutical company clinical research in 
South Africa from 2000 to 2003, inclusive, through a cross-sectional quantitative 
survey of pharmaceutical companies in the country. 
• Compare the company disease priorities with the Medical Research Council’s 
South African National BoD Estimates for 2000 (Deaths, Years Life Lost (YLLs) 
and Disability Adjusted Life Years (DALYs)) in order to identify areas of 
alignment and gaps (Definitions). 
• Examine the processes and criteria pharmaceutical companies use to decide 
upon research priorities in the country via a qualitative analysis of interviews from 
purposively selected companies. 
 
1.3 The Importance of Investigating Health Research Priority Setting 
Bradshaw et al argued, “In the health sector scarcity of resources makes priority setting 
imperative” (Bradshaw et al 2003b, 1).  This sentiment was a predominant theme in the 
literature.  In 2001, the South African Department of Health released a ‘Health Research 
Policy in South Africa’ which stated that, “Due to the transformation of the health care 
delivery system and the need to address the pressing health and development 
challenges in the country, it is imperative that health research priorities be determined 
for South Africa in both the short and long term”   (DoH 2001, 2).   The South African 
National Health Act created a National Health Research Committee to identify and 
coordinate public health research priorities (Republic of South Africa 2002; COHRED 
2001).  At the international level, the World Health Organisation Advisory Committee on 
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Health Research created a handbook on health research priority setting which stressed 
that “Resources are finite…different options need to be weighted before resources are 
allocated and a course of action decided.  The overall goal is to allocate resources more 
effectively” (WHO 2001, 2). 
 
Much of the literature on the importance of health priority setting comes from the public 
sector point of view – how to allocate national resources to improve a country’s 
population health.  There were few studies on health research priority setting from the 
private sector perspective – how to provide health care to a consumer market within a 
company’s limited resources.  However, some studies combined perspectives and 
discussed the importance of leveraging private pharmaceutical company research to 
focus on diseases of public need because of the unique nature of the industry in that it 
operates according to private market principles yet its research efforts can impact public 
health (Comanor 1996; Michaud and Murray 1996; Trouiller, Torreele, Olliaro et al 2001; 
Webber 2003). 
 
1.4 Comparison of Health and Pharmaceutical Research in Relation to Burden of 
Disease 
There has been an increasing interest at global and country levels in comparing public 
and private research with the BoD as a mechanism for priority setting.  The assumption 
for this comparison is that research should be aligned with burden of disease based on 
the principle that limited resources ought to be allocated to the greatest needs.  For 
example, in the forward to South Africa’s first burden of disease study, William Pick 
stated, “Country-specific estimates of the burden of disease are crucial for targeting 
health interventions that make a significant impact on the well-being of the population” 
(Bradshaw et al 2003a).  In reference to new vaccine development and use, Levine and 
Levine found that, “disease burden seems like an obvious quantitative measure for 
setting priorities” (1997, 1386).  Several studies compared BoD with research such as 
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the Global Forum for Health Research’s work that coined the term “10/90 gap” that arose 
from its estimates that 10% of the more than US$70 billion spent worldwide on health 
research and development by the public and private sectors is used for research into 
90% of the world’s health problems (Global Forum for Health Research 2002, xv).  
Canada, Australia and the United States have examined their national research funding 
in relation to their country’s BoD (Lamarre-Cliché, Castilloux, LeLorier 2001;  Aoun, 
Pennebaker, Pascal 2004; Gross, Anderson, Powe 1999).  In South Africa, one study 
compared the percentage of conference presentations dedicated to mental health issues 
with mental health priorities (Flisher, Parry, Stein 2000) and another study calculated 
ratios of the amount of published randomised clinical research in sub-Saharan Africa 
with the respective BoD (Isaakidis, Swingler, Pienaar et al 2002).   
 
With specific regard to pharmaceutical industry research, several reports showed that 
few companies research, develop and launch drugs for neglected diseases (Comanor 
1996; Michaud and Murray 1996; MSF/DND Working Group 2002; Yamey 2002).  
Isaakidis et al argued that companies are reluctant to conduct research in diseases that 
affect few people, or the poor populations of developing countries (Isaakidis et al 2002).  
Resnik explained that this “can leave large gaps in our medical knowledge and may fail 
to promote the interests of all people in society” (Resnik 2003, 1).  However, the major 
challenge with examining the private pharmaceutical industry was the lack of data.  
Michaud and Murray found that only three companies at the international head office 
level returned their questionnaire and, “The paucity and lack of comparability of available 
disaggregated data did not allow us to assess the level of funding allocated to specific 
health problems with a sufficient level of confidence” (1996, 217).  Therefore, although it 
was recognised that South Africans also benefit from research conducted outside of the 
country, the difficulties in obtaining international clinical trial level data informed the 
design of this study such that it focused only on research conducted in South Africa. 
 
MPH Research Report: J Hoerter 0310496H   4
No studies in South Africa were identified which quantified pharmaceutical company 
research according to disease category.  The only studies found were general estimates 
of pharmaceutical expenditure on research (PMA 1997; Wits Health Consortium 2000; 
Department of Science and Technology 2003). Nor were any studies found which 
compared pharmaceutical company research to the country’s disease burden.  Perhaps 
this is because the country’s first ever BoD estimates were only reported by the Medical 
Research Council (MRC) relatively recently in March 2003. The MRC report “displays 
the quadruple burden of disease experienced in SA: a combination of pre-transitional 
diseases and conditions related to under-development and poverty, the emerging 
chronic diseases associated with affluence, a high injury burden and the extensive 
HIV/AIDS epidemic” (MRC 2003a, 5).   These findings supported the growing 
significance of non-communicable diseases which was recognised in the WHO Global 
Burden of Disease report for the sub-Saharan region (Murray and Lopez 1996) and ran 
counter to the “conventional wisdom that non-communicable diseases are not a high 
priority area for health research and development in the countries of sub-Saharan Africa” 
(Unwin, Setel, Rashid et al 2001, 947).  Therefore, it was apparent that South Africa’s 
unique BoD profile reflecting challenges of both the developed and developing world 
was important to consider in this study. 
 
1.5 Understanding How Priorities are Set  
The literature investigating how priorities are generally set focused first on the objective 
trying to be achieved.   It was a common approach to analyse alternative priorities in 
terms of their ability to impact an objective, yet as the International Service for 
Agricultural Research discovered, “the evaluation does not yet result in clear priorities 
since several objectives are usually involved [and] priority setting includes the 
determination of the relative importance of these objectives” (ISNAR 2002, 1). 
 
With regard to health research priority setting, the co-existence of multiple objectives 
across stakeholders was readily apparent in the literature.  The South African 
MPH Research Report: J Hoerter 0310496H   5
Department of Health’s objective was to “improve human health and well-being” (DoH 
2001, 2).  Resnik suggested that companies’ objectives were to make a profit and 
priorities were based on “market potential, liability costs, the scope of intellectual 
property protection, market lead time, the expected time from the laboratory to the 
market, and other factors that affect the profitability of a research investment” (Resnik 
2003, 1).   In an Australian study on stakeholder priorities for mental health, “different 
groups of stakeholders tended to have differing perspectives on research priorities, with 
some major differences between committees that evaluate research grants and 
consumer and carer groups” (Griffiths, Jorm, Christensen et al 2002, 327).  This 
illustrates that governments, private sector and patients can all have different objectives 
and that it is critical to clarify whose objective is trying to be met when understanding 
how health priorities are set.   
 
Recognition of multiple objectives is particularly relevant to this study because much of 
the concern in the literature that pharmaceutical research does not reflect a country’s 
BoD arises when public sector objectives of reducing a population’s overall BoD may 
clash with private sector objectives of providing medicines to a consumer market.  
Therefore, how to stimulate private research in the areas of public need was heatedly 
debated in several articles.  It appeared that the differences in objectives was not 
recognised nor the constraints of the respective parties understood.  For instance, 
arguments that companies have an inherent social responsibility to the developing world; 
did not recognise that there are other “economic, social, legal, political and obligations 
and commitments companies face” (Resnik 2001, 11).  Resnik further suggested that, 
“developing countries can work toward attracting research and investment rather than 
just expect it.  For example, they can adhere to intellectual property treaties, insure 
companies have a good business environment by promoting rule of law, ethical business 
practices, stable currencies, reliable banking systems, free and open markets, and 
democracy” (Resnik 2001, 11).  However, on the other side, arguments that countries 
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should create an inviting atmosphere for pharmaceutical companies to conduct research 
did not recognise that countries often did not have the scientific capacity, had negative 
experiences with clinical trials in the past, or could not afford to pay international market 
prices for new medicines (Shah 2003).  For those articles that did incorporate the market 
dynamics of the pharmaceutical industry, the focus was on how to change the current 
market such that private company objectives could be met and public health needs 
would not be neglected (Trouiller et al 2001). 
 
Numerous articles devised frameworks for setting health research priorities and each 
incorporated some measure of BoD.  However, most frameworks also stressed the 
importance of other parameters such as risk factors for disease, current state of 
knowledge, availability of data, feasibility and cost-effectiveness, potential impact of an 
intervention, geographic distribution, human and financial resources, ethical and equity 
issues, and the role of actors and processes involved in decision-making. Other 
frameworks took these factors one step further and examined priority setting at the 
individual, local, national, regional and global levels (Levine and Levine 1997; COHRED 
2001; Schneider 2001; Global Forum for Health Research 2002; Republic of South 
Africa 2002; WHO 2001; Francisco 2004).  Shortcomings of these paradigms were also 
debated and Fraser identified core problems where, i) there is little known about the 
health problem, ii) current control methods are unsustainable, iii) there are complex risk 
factors, and iv) the disease burden and resources for control vary greatly from one place 
to another (Fraser 2000, 1054).   
 
With regard to the private pharmaceutical industry specifically, additional considerations 
were raised, such as: 
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• External factors - macroeconomic stability, tax incentives, trade policies, judicial 
systems, regulation, intellectual property rights, human resources, public research, 
education system, natural resources and information networks 
• Market factors - overall market size, the public perception of risk associated with the 
disease, government and private purchasing, pricing, product liability, competitors, 
and anticipated return on investment 
• Internal factors - technological feasibility and cost of development and production, 
probability of success and expertise of the company (both in research & 
development and marketing). (Dupuy and Freidel 1990; Levine and Levine 1997; 
CMCS 2001; Trouiller et al 2001; Andre 2002; Webber 2003).   
 
There was little agreement in the literature on how to set public or private health 
research priorities, but all did include some form of burden of disease measure as a 
criterion.  The authors did concur that the process is complex and the inclusion of 
multiple parameters was essential. 
 
1.6 Methods for Health Priority Setting Studies 
In light of the multi-faceted nature of priority setting, specific concerns were raised with 
regard to comparing research solely to BoD as a method for priority setting.  Harold 
Varmus, M.D., USA, and Head of the National Institutes of Health (NIH) in 1999, felt that 
“it is important to emphasize that there is not – and should not be – an absolute 
correspondence” [between NIH funding and the BoD] because of the inherent 
methodological difficulties and the importance of other factors in priority setting” (Varmus 
1999, 1914).  Moreover, “assessing research according to money spent on a specific 
disease is imprecise” (US Dept of Health and Human Services 2004, 2) and the 
“serendipitous nature of science must be considered; investigations in one area 
frequently yield fruitful results in another…Hence, it may be overly simplistic to link 
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funding to specific diseases.  However, awareness of this factor does not preclude the 
need for rational methods to assign priorities…” (Gross et al 1999, 1886). 
 
Varmus further argued that policy makers should not just focus on current burdens of 
disease, but they need to consider “projections of future patterns of disease  and  the 
effects of demographic changes (such as aging) and personal habits (such as tobacco 
use)…” (Varmus 1999, 1914).  Others suggested that “disease focus is only one 
dimension of health research and…major risk factors affecting health also have to be 
prioritised” (Global Forum for Health Research 2003, 1).  The World Health Report 2002 
reflected this concern by identifying 10 risk factors that account for more than a third of 
worldwide deaths (WHO 2002), and the MRC’s BoD report also drew attention to the 
importance of risk-prevention strategies (Bradshaw et al 2003a, xi). 
 
Furthermore, the literature revealed that BoD calculations are evolving and are not yet 
100% accurate for use as a method for priority setting.  Traditionally, mortality data was 
used as a BoD indicator; however, new measures that incorporate premature mortality 
and morbidity now provide a more comprehensive picture of the BoD.  Such measures 
are: Years Life Lost (YLLs), “calculated by subtracting a person’s age at death from his 
or her life expectancy in the absence of a given disease” (Gross et al 1999, 1882); and 
Disability Adjusted Life Years (DALYs), “calculated by estimating Years Life Lost (YLL) 
and Years Lived with Disability of known severity and duration (YLD) and then adding 
them.” One DALY is one lost year of healthy life (Murray and Lopez 1996, 7). 
 
However, two main concerns emerged from the literature with regard to the calculation 
of BoD measures: 1) technical issues, and 2) the social values incorporated into the 
measures (Gross et al 1999, 1885).  Technical issues stem from the lack of quality data.  
There is often no central repository of data, reporting errors and improper coding are 
common, composite measures are difficult to break down, proxy measures are 
MPH Research Report: J Hoerter 0310496H   9
imprecise, and some diseases impact morbidity of other diseases - all which impact the 
validity of BoD measures (Gross et al 1999; Morrow and Bryant 1995; Murray and Lopez 
1996; Schneider 2001).  Social values incorporated into BoD measures also result in 
variability because not all people agree on what is ideal life expectancy, how valuable is 
healthy life in young adulthood versus older age, which disability is more severe than 
another, or is living with a disability better than premature death? In addition, other 
personal judgments such as the value of incremental improvements in health, co-
morbidity, gender, equity, poverty, cost-effectiveness and avoidability add to the 
inconsistency of BoD calculations (Bradshaw et al 2003a; Gross et al 1999).   
 
Therefore, although the literature supported the use of BoD as a criterion in the design of 
priority setting frameworks, it suggested that it should not be the sole criterion for 
comparing research with health needs and was clear on its limitations (Morrow and 
Bryant 1995; Murray and Lopez 1996; Schneider 2001).   
 
Lastly, a variety of comparative methodologies were used in general health priority 
setting studies identified in the literature.  Studies evaluated multiple BoD measures that 
included incidence, prevalence, hospital days, death, YLLs and DALYs.  Furthermore, 
different indicators of research were assessed such as expenditure on trials and number 
of publications.   For studies that compared multiple measures, all concluded that the 
results were highly dependent on which measure was used (Aoun et al 2004; Gold and 
Muennig 2002; Gross et al 1999).  Statistical techniques used included percentage 
comparisons, ratios, correlation coefficients, and regression analyses, and the studies’ 
results also depended on which statistic was used (Aoun et al 2004; Gross et al 1999; 
Jorm et al 2002; Lamarre-Cliché et al 2001; Swingler et al 2003).  Therefore, authors 
cautioned that “policy makers could be misled by using a single burden of disease 
[measure]”, or measure of research, or comparative statistic because “advocates 
interested in promoting research on particular diseases could select measures that best 
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support their cause” (Gross et al 1999, 1885-6).  It was apparent that there is no well-
established methodology for health priority setting studies in general and that 
interpretation of any such study should be made clearly within the context of its study 
design. 
 
1.7 Implications of the Literature Review  
The literature revealed that the aims of this study to identify pharmaceutical company 
research priorities in South Africa and compare them with the country’s BoD were 
important because there is little data on health research priority setting from the private 
pharmaceutical sector perspective.  A better understanding of how pharmaceutical 
companies prioritise their disease research in the country would enhance public and 
private decision-maker’s ability to devise practical policies to support company research 
in diseases of need. 
 
In summary, key issues raised in the literature that are important to this study are: 1) the 
importance of various stakeholder objectives, 2) the multi-faceted nature of health 
research priority setting, 3) the limitations of relying solely on BoD as a comparative 
indicator for health need, and 4) the need to compare multiple measures of research and 
BoD with a variety of statistical tools in order to have a more complete picture of their 
relationship.  Furthermore, although it was recognised that South Africans also benefit 
from research conducted outside their country, the same difficulties in obtaining disease-
specific research data from companies’ global offices by other researchers was 
anticipated with this study, which resulted in limiting its scope to research in South 
Africa.  These key issues greatly informed the design and interpretation of this study, 
and pending the development of other comparators and methodologies, the results of 
this study remain instructive since no such baseline has ever been established. 
 
MPH Research Report: J Hoerter 0310496H   11
2.0 Methods  
The study design, sampling method, sample size and characteristics, processes used for 
data collection and measurement,  ethical  and confidentiality considerations, and data 
analysis are addressed below. These are followed by limitations of the study design.  
 
2.1 Two-Part Study Design 
 
Part One of this study was cross-sectional and descriptive. It compared quantitative data 
collected through questionnaires completed by participating pharmaceutical companies 
in South Africa with the South African Medical Research Council’s BoD estimates for 
2000, which included Deaths, Years Life Lost (YLLs) and Disability Adjusted Life Years 
(DALYs). 
 
Part Two of this study was exploratory and involved thematic analyses of qualitative data 
collected through semi-structured interviews with Medical Directors from purposively 
selected pharmaceutical companies. 
 
2.2 Study Population 
The source for the study population comprising all pharmaceutical companies in South 
Africa was the 2003 South African MIMS Desk Reference (compendium of 
manufacturers and medicines) that listed 79 pharmaceutical companies operating in the 
country (MIMS 2003).  It was the most comprehensive list of companies publicly 
available. 
 
Inclusion criteria were: 
- Pharmaceutical companies registered in South Africa. Rationale: Only companies 
with products available in South Africa could potentially meet the country’s BoD.  
Furthermore, it was impractical to assess global research due to the lack of available 
data. 
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- Clinical trials that received approval by an accredited South African Ethics 
Committee. Rationale: Only those trials approved by an accredited South African 
Ethics Committee were appropriate to consider and obtaining ethics approval 
demonstrated a company’s intent to conduct research in a particular disease 
category. 
- Clinical trials that received ethics approval during the period from 1 January 2000 to 
1 January 2004.  Rationale: Four years provided a sufficient range of data, and trials 
before 2000 were excluded because the data was difficult to obtain due to numerous 
pharmaceutical company mergers. 
- Clinical trials for an investigational product without a generic equivalent available on 
the South African market at the time of Ethics Committee approval. Rationale: 
Research aimed at identifying new medicine to address unmet medical needs was 
the focus of this study.  
− Multiple trials relating to the same investigational product.  Rationale: It is possible to 
have multiple trials researching a new indication, strength, dosage, or drug delivery 
system for the same product. Each trial was indicative of research in specific disease 
category. 
− Clinical trials that were either conducted in full by a pharmaceutical company or out-
sourced to a Contract Research Organisation (CRO). Rationale: Small and large 
companies alike often do not have capacity to manage their own research so trials 
were sometimes contracted out, but with local company oversight. 
 
Exclusion criteria were: 
- Clinical trials on generic equivalents, such as bioequivalence or pharmacovigilence 
studies.  Rationale: Research on existing molecules does not address the need for 
new medicines for unmet medical needs. 
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- Clinical trials on medical devices or diagnostic equipment not specifically related to 
an investigational product (e.g., stents, pacemakers, dialysis supplies). Rationale: 
The scope of this study was medicine only. 
- Clinical trials conducted by Contract Research Organisations (CROs) for parent 
companies outside of South Africa without the knowledge of local affiliate. Rationale: 
This rarely happens nowadays, and this data was not feasible to obtain. 
- Clinical trials conducted by Contract Research Organisations (CROs) for companies 
not registered in South Africa. Rationale:  Only companies that are registered in 
South Africa were included. 
- NGOs and government research. Rationale: This study focused only on the 
pharmaceutical industry. 
 
In summary, the inclusion and exclusion criteria limited the study population to 
pharmaceutical companies registered in South Africa that were conducting clinical trials 
approved by an accredited ethics committee for new medicines.   
 
2.3 Sampling Method 
Data on pharmaceutical company clinical trials was not available through either the 
Medicines Control Council (MCC) or the more than 20 Ethics Committees.  
Computerised records were not often kept, disease categories were not consistently 
captured, and most importantly, confidentiality of each company’s data needed to be 
maintained by the respective custodian of information (MCC 2003a, 2003b; SAAPP 
2003).  Therefore, data for this study had to be obtained directly from each company. 
 
 
Sampling method – Part One 
All of the 79 companies listed in the 2003 MIMS Desk Reference were considered. To 
ensure completeness, the MIMS list was cross-referenced with member lists from 
physician, pharmacist, and pharmaceutical company trade associations involved in 
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clinical trials and no gaps were found (SAAPP 2003; Wits Health Consortium 2000; 
IMSA 2003; PMA 2003) 
 
Each company was then contacted via phone or email to determine if they met the 
inclusion criteria.  24 companies met the inclusion criteria and follow up meetings were 
held with each of their Medical Directors to assess their willingness to participate.  18 
companies agreed to participate, and 17 companies actually completed the 
questionnaire that resulted in a 70.86% response rate for Part One (17 out of 24 
companies).   The 24 eligible companies represented more than 61% of private 
pharmaceutical market sales, and the remaining 39% of the private market was from 
non-eligible companies.  The 17 participating companies represented more than 44% of 
the private market (IMS 2003).  Public market figures were unavailable.  The 17 
participating companies represented a good range of sales, clinical research staff, 
disease priorities, headquarters location and number and types of trials.  Therefore, 
although the sample was non-random, it was a substantial portion of the study 
population.  It was inappropriate to select a smaller sample size since it was feasible to 
include all 24 eligible companies, and 17 participating companies was sufficient for the 
descriptive purposes of this study.  The characteristics of the 7 non-participating 
companies did not differ greatly from the participating companies.  Given the confidential 
nature of this study and the small sample size, further exploration into non-responders 
was not conducted so as to preserve the confidentiality of the participants and non-
participants. 
 
Sampling method – Part Two 
After completion of the questionnaires, three (3) Medical Directors from companies with 
the lowest number of trials and three (3) Medical Directors from companies with the 
highest number of trials were selected for interviews.  One of the companies with a low 
number of trials was unavailable for an interview and was replaced with another 
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company with an average number of trials.  A larger sample for interviews was not 
chosen because the goal was not statistical inference, but rather to explore qualitatively 
how companies prioritise disease categories for research.  Although purposive sampling 
did not enable precise generalisations about the study population, a sufficient range of 
company sizes and disease priorities were represented which was important so that the 
results would enable any potential differences due to company size or disease focus to 
emerge.   
 
2.4 Data Collection and Measurement 
In order to improve the quality of both the questionnaire and interview response rates, 
pre-meetings were held with members of the Pharmaceutical Manufacturers Association 
(PMA), Innovative Medicines South Africa (IMSA) and the South African Association of 
Pharmaceutical Physicians (SAAPP) in order to generate interest in participation.  The 
questionnaire and interview questions were piloted with 3 Medical Directors to check for 
understanding, fine-tune questions, assess feasibility and time required to obtain data.  
These 3 Medical Directors were from companies that were part of the final sample. 
However, since the questionnaire did not change significantly between the Medical 
Director’s preview and the final version, their familiarity with the questionnaire did not 
negatively impact the study, and perhaps improved their ability to fill it out correctly.    
 
Data collection and measurement – Part One 
The questionnaire in Part One of the study had two-parts.  Part I of the questionnaire 
asked contextual questions in order to characterise the scope of the company’s research 
in South Africa, which included what the company’s top 5 disease priorities were 
(referred to as company priority in the results).  This study did not seek to quantify 
expenditure due to the challenge of accessing verifiable financial data. Part II of the 
questionnaire asked specific questions relating to each clinical trial, which included what 
was the trial’s disease target (referred to as trial priority in the results), phase, number of 
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planned and final participants, and number of planned and final sites (Appendix 1 – 
Company Questionnaire).  The questionnaire was distributed and returned electronically 
within 1 to 14 weeks after regular phone calls and emails to kindly remind participants. 
Companies self-reported results, and I entered the data into a Microsoft Excel®  
spreadsheet (Microsoft 2000).  I then verified the data by double-checking the 
questionnaires with the Excel® spreadsheet twice and any anomalies were confirmed 
with the respective company. 
 
In order to achieve a true comparison of  disease categories  between pharmaceutical 
company research and  the MRC’s  BoD study, permission was received from Debbie 
Bradshaw at the South African Medical Research Council to use the same disease 
codes for this study as those that the MRC devised for their National Burden of Disease 
study (Bradshaw 2003).  However, not all of the 24 MRC disease categories were 
amenable to pharmaceutical intervention (e.g., cot death) and it would have been 
inappropriate to compare pharmaceutical clinical research with such disease categories.  
Therefore, 3 medical doctors, who were not participants in the study, were consulted to 
advise on which disease categories of the MRC’s BoD study should be excluded for this 
reason. The doctors identified: nutritional deficiencies, congenital abnormalities, cot 
death, unintentional injuries and intentional injuries.  These 5 disease categories were 
then excluded, and the remaining 19 MRC disease categories were used for this study’s 
comparative calculations.  A 20th category “Other” was added to capture those 
conditions or disorders which the MRC had not included in their taxonomy (e.g., pain, 
smoking addiction) and were reported descriptively (Appendix 3 - Disease Categories 
and Codes). 
 
Data collection and measurement – Part Two 
The exploratory interviews in Part Two of the study were based on three open questions 
which identified the process and timing for how the company decides to conduct clinical 
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trials in South Africa, what issues or factors the company considers when deciding to 
conduct a trial, and why the company prioritises disease categories for research in South 
Africa in the way that they have (Appendix 2 – Pharmaceutical Company Semi-
Structured Interview Questions).  
 
The questions were asked during telephone interviews with Medical Directors, given 
difficulties of arranging face-to-face interviews.  The interviews were not recorded, but 
diligent notes were taken and at the end, a summary of the response was recited back to 
the participant to ensure accuracy.  The accuracy of my summary feed-back was 
commended by all 6 interviewees.  The interview data were then transcribed by me into 
an Excel® spreadsheet for further analysis.  Statements by interviewees were coded 
according to common themes that emerged from them, and the data was then tabulated 
by code across interviews to allow similarities and differences between the interviews to 
be identified. 
 
2.5 Data Analysis 
Quantitative Analysis – Part One 
First, summary descriptive statistics were calculated in Excel® for each measure of 
company research per disease category:  
1) total number of diseases reported as one of the top 5 company priorities  
(company priority);  
2) total number of diseases reported as a trial priority (trial priority);  
3) total number of participants planned (participants planned); 
4) total number of participants enrolled٭ (participants enrolled);  
5) total number of sites planned (sites planned); and, 
6) total number of final sites (sites final).   
٭ participants ‘enrolled’ means the participants signed informed consent 
The measures of company research by disease category were not weighted (i.e., 10 
trials equalled 10 participants planned for cardiovascular disease).  It would have been 
an imprecise exercise to rationalise why one measure of company research should be 
weighted more than another (i.e., why trials may be more important than participants 
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planned).  Moreover, no other previous comparative BoD study identified in the literature 
review weighted measures of research. 
 
Second, any data outliers (extreme values or omissions) were verified with the 
respective company. Sub-analysis summarised the number of clinical staff, phases of 
trials, prevention and/or treatment trials, multi-country trials, registration status of the 
product, and trials contracted out. 
 
Third, comparative statistical analysis was performed between the measures of 
company research and the MRC BoD measures (Deaths, YLLs, DALYs).  Multiple 
measures of BoD were used as comparators to address one of the key methodological 
issues revealed in the literature review, namely the variability of results depending on 
which BoD was used as a comparator.  Furthermore, Debbie Bradshaw suggested that 
the quality of the DALYs in the MRC report were not as robust as the Death and YLL 
data (Bradshaw 2004).  Therefore, this study examined all three MRC BoD comparators: 
Death, YLLs and DALYs. 
 
The use of multiple comparative statistical analyses using rankings (Spearman’s rank 
coefficient of correlation) and actual values (Pearson’s coefficient of correlation and 
Regressions) was an integral part of this study’s design so that any potential variations 
in the  results due to the  use of  different statistical tools could  emerge.  This  was an 
intentional effort to address another methodological issue that was identified in the 
literature review, namely that results of other comparative BoD studies differed 
depending on which statistical tool was used. 
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For the comparative statistics, all data were transformed by taking the logarithm*.  This 
was important to do because the wide range of actual values (0 - 5 067 490) was too 
broad to see any patterns.  Other comparative BoD studies identified in the literature 
review also logged their data (Gross et al 1999), and because for regressions “suitable 
transformations of data can sometimes be found that will permit a nonlinear model to be 
approximated by a linear one (Weisberg 1985, 141),”  it was decided that logging the 
data would provide the best format for analysis.   
 
Non-parametric statistical analysis using Spearman’s rank coefficient of correlation was 
conducted to determine the relationship between the relative rankings of the measures 
of research and the MRC’s BoD measures (logging had no impact on ranks).  Then, 
parametric statistics using Pearson’s coefficient of correlation were calculated to 
determine the relationship between the actual values (logged) of the respective 
measures.  Both Spearman’s rank and Pearson’s correlations were then conducted 
again excluding HIV/AIDS given the high value of HIV/AIDS in all BoD measures.  The 
criterion for significance was p < 0,05 for a two-tailed test.  
 
The Spearman’s rank and Pearson’s correlation coefficients only summarised the data in 
a single number and did not clearly identify alignment and gaps for specific diseases 
with the BoD measures.  Therefore, it was essential to perform regression analysis with 
the actual logged values (not the ranks) and then plot the regressions to better illustrate 
and adequately differentiate which diseases were in alignment and which were not.  For 
this reason, those regressions with both a Spearman’s and Pearson’s statistical 
significance of < 0,05 were plotted to visualise gaps and alignment for specific disease 
categories.  (The remaining regressions were also plotted but there was too much 
variability to draw conclusions). 
                                                
MPH Research Report: J Hoerter 0310496H   20
* Because there were 0 Deaths and YLLs for the Sense Organs and Oral Conditions disease categories, in order to log 
transform the data, dummy figures of 2 Deaths and 2 YLLs for sense organs and 1 Death and 1 YLLs for oral conditions 
were added upon advice from the MRC.  These low substitute numbers did not impact the results, but did allow the data 
to be logged.  Lastly, all data was logged at “x + 1” due to a few variables with 0 observations. 
  
This resulted in Spearman, Pearson and regression calculations using Stata® Statistical 
Software (Stata 2003) for all 19 MRC disease categories for the following measures*: 
                                                
* Predictive variables (X) 
- MRC’s 2000 South African burden of disease estimates for Death, Years Life Lost (YLLs) and Disability 
Adjusted Life Years (DALYs)  
(Table 2: MRC Burden of Disease Estimates, 2000) 
 
and; 
 
Dependent variables (Y) 
- Number of company priorities, trial priorities, participants planned and enrolled, sites planned and final 
(Table 1: Company, trial and participants planned disease priority numbers and rankings, and; 
Appendix 5: Participants enrolled, sites planned, and sites final disease priority numbers and 
rankings). 
 
- Companies vs. Deaths 
- Companies vs. YLLs 
- Companies vs. DALYs 
 
- Trials vs. Deaths 
- Trials vs. YLLs 
- Trials vs. DALYs 
 
- Participants planned vs. Deaths 
- Participants planned vs. YLLs 
- Participants planned vs. DALYs 
 
- Participants enrolled vs. Deaths 
- Participants enrolled vs. YLLs 
- Participants enrolled vs. DALYs 
 
- Sites planned vs. Deaths 
- Sites planned vs. YLLs 
- Sites planned vs. DALYs 
 
- Sites final vs. Deaths 
- Sites final vs. YLLs 
- Sites final vs. DALYs 
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Qualitative Analysis – Part Two 
First, interview responses that were in common or unique were identified, counted and 
coded into categories.  Sub-codes were allocated to further differentiate within 
categories.  Second, similarities and differences across interviews were examined to 
identify any relationship between the size of the company and/or its disease specialties 
and the responses. Third, the broad themes were compared with the quantitative 
responses from the questionnaire, opinions found in the literature review, and my own 
expectations that were formed as a result of my initial consultations with industry and 
public health experts while piloting the questionnaire. For example, the high amount of 
research for cardiovascular disease found in the questionnaire was evaluated within the 
context of the multi-faceted nature of priority setting and the limitations of relying solely 
on BoD that were revealed in the literature review, along with my expectations that 
companies may rely on more than BoD criteria to prioritise their research as was 
mentioned to me in preliminary discussions.  This process enabled me to systematically 
interpret the qualitative interview findings and explain the results of the quantitative 
questionnaire (i.e., what company disease priorities are and how and why companies 
may choose them). 
 
2.6 Ethical and Confidentiality Considerations 
Approval of the study protocol by the University of the Witwatersrand Faculty of Health 
Sciences was received on 4 December 2003, protocol # M03-09-16.  Ethics clearance 
was received by the University of the Witwatersrand Committee for Research on Human 
Subjects (Medical) on 3 September 2003.  Furthermore, informed consent for both the 
questionnaire and in-depth interview was signed by each participant, and confidentiality 
agreements were signed between each participant and myself to protect company- and 
individual-specific data.  Also, although my advisor and statistician did not receive any 
company- or individual-specific data, confidentiality agreements were signed with each 
of them to protect aggregate industry data.  There were no financial or non-financial 
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incentives for participants, and I had no affiliation or support from any company or 
industry association.  Non-responders and responders were not identified nor described 
in order to preserve their confidentiality. 
 
2.7 Limitations 
There were some potential limitations in the study design regarding selection, 
measurement and other biases, however, all reasonable effort was undertaken to 
minimise them. 
 
Selection bias 
Selection-bias could have been introduced given that only those companies willing and 
able to provide data participated.  Furthermore, those companies that expected their 
research to be line with the BoD may have been more willing to participate which could 
have biased results to be more in line with BoD, and those companies that expected to 
be out of line may have opted not to participate.  However, selection bias was 
considered minimal because the final response rate was 70,86% (17 out of 24 eligible 
companies participated) and the data represented a good range of sales, clinical 
research staff, disease priorities, headquarters location and number and types of trials.  
Non-response was minimised through numerous pre-meetings with all eligible 
companies, industry associations, and follow-up phone calls to encourage participation.  
Also, assurances of confidentiality were formalised through informed consent and 
confidentiality agreements with each participating company.  However, due to the 
confidential nature of the study design, characteristics of non-responders were not 
reported so it is unknown how many trials out of the potential total are missing, but it is 
considered to be minimal. 
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Measurement bias 
A major advantage of this study was that the companies directly provided the information 
so there was little room for third party mistakes.  However, a potential disadvantage was 
that measurement bias could have been introduced because the data was not verifiable 
through other sources due to the confidential nature of the study. Companies may have 
inaccurately reported either unintentionally by misinterpreting the question or definitions, 
or through questionnaire fatigue; or intentionally, by reporting only those trials that 
favourably reflect the BoD.  Unintentional mistakes were minimised by piloting the 
questionnaire to improve its precision, being available throughout the process to answer 
any questions, and verifying any identified anomalies.  Intentional mistakes were 
considered minimal because this study’s company reported disease priorities did reflect 
the areas of expertise mentioned in the company annual reports and/or the company’s 
current product range.  Furthermore, the interviews were completely voluntary and 
confidentiality was maintained so there was no reason to believe that the answers did 
not reflect the opinion of the interviewee. 
 
Other biases 
Investigator bias could have been introduced during the data collection, analysis or 
interpretation because of my previous 9 years of experience in the pharmaceutical 
industry.  My experience was actually an advantage because it assisted me in gaining 
access to the companies.  Furthermore, this research topic was completely my own idea 
and neither my previous employers nor any other pharmaceutical company or 
association was affiliated with or funded the study.  Potential bias was minimised by 
adhering to conventional statistical methods for the calculations and using accepted 
qualitative techniques such as such as comparing and contrasting findings amongst the 
interviews and external sources (Data Analysis).  In addition, two independent 
researchers, my advisor and statistician, reviewed my practices. 
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3.0 Results  
First, the descriptive and comparative analysis for Part One’s quantitative results are 
presented, and second, Part Two’s qualitative results are shown.  Lastly, links between 
the quantitative and qualitative findings are described. 
 
3.1 Descriptive Quantitative Results – Part One 
 
The response rate was 70,86% (17 companies completed and returned a questionnaire 
out of 24 eligible companies) and the total number of trials reported was 214.  The 
average number of trials per company was 12,59 and the median number of trials per 
company was 11 (interquartile range 7 to 20).  
 
Of the 19 MRC disease categories plus one “Other” category for  those diseases  the 
MRC taxonomy did not capture, the leading diseases which companies reported on the 
questionnaire as one of their top 5 priorities were: cardiovascular disease, mental 
disorders, musculo-skeletal diseases, respiratory infections, endocrine and metabolic 
disorders, and infectious and parasitic diseases (excluding HIV/AIDS).  Maternal, oral, 
and perinatal conditions were not identified by any company as one of their top 5 
priorities (Figure 1).  The leading number of trials were in cardiovascular disease, 
malignant neoplasms, mental disorders, diabetes mellitus, and respiratory disease.  No 
trials were reported for maternal, perinatal and oral conditions, or benign neoplasms 
(Figure 2).   Only two company priorities and two trials were categorised as “Other”.  
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Figure 1: Total Number of Companies which Reported Disease as One of Their Top 5 
Priorities 
Total # of Companies which Reported Disease as One of Their Top 5 priorities
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The highest number of Phase I trials were in diabetes and mental disorders, and for 
Phase II, malignant neoplasms and mental disorders trials were most numerous.  For 
Phase  III, the  highest number of trials was for cardiovascular disease and malignant 
neoplasms, and for Phase IV, cardiovascular disease trials were the most numerous.  
No trials for maternal, perinatal and oral conditions were reported for any phase (Figure 
2). 
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Figure 2: Total Number of Trials Reported per Phase and Disease Category 
Total Number of Trials Reported per Phase and Disease Category
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For all trials, the total number of participants planned was 16 961, and the total number 
of participants enrolled was 23 200.  A similar pattern of final numbers exceeding 
planned was found for sites (1 650 planned and 1 703 final sites).  It appeared that 
companies not only met, but exceeded their expectations, or perhaps they 
underestimated the final number of patients and sites during their initial planning phase.  
Disease priorities in relation to the number of participants and sites showed that 
cardiovascular disease and musculo-skeletal diseases were the highest priorities, and 
no participants or sites were reported for maternal, perinatal and oral conditions 
(Appendix 4 – Participants planned and enrolled, sites planned and final per disease 
category). 
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In summary, across measures of company research (company, trial, participant and site 
disease priorities), cardiovascular disease was the top priority, and maternal, perinatal 
and oral conditions were not reported as priorities. However, it is important to note that 
disease priority rankings differed considerably among the company, trial and participants 
planned measures of research as illustrated in Table 1 (and seen for all other measures 
of research in Appendix 5 – Participants enrolled, sites planned and sites final numbers 
and rankings per disease category).   For example, although diabetes ranked 10th for 
company priority and 8th for participants planned, it ranked 4th for trials; and HIV/AIDS 
ranked 7th for company priority and trials, yet it was 4th for participants planned. This 
reinforces the importance of clearly identifying which measure of research is being 
examined when reporting results as discussed in the literature review. 
 
3.2 Comparative Quantitative Results – Part One 
 
The extent to which pharmaceutical research in South Africa reflected the country’s BoD 
was highly dependent on which measure of company research was examined (e.g., 
companies, trials, participants, sites, etc.) and which measure of disease burden was 
used as a comparator (e.g., Deaths, YLLs, DALYs).  For example, Section 3.1 above 
showed how disease priorities differed depending on whether company or trial priorities 
were assessed.  Disease priorities also differed depending on the MRC BoD measure 
considered (e.g., cardiovascular disease ranked 2nd in  Deaths, 4th in YLLs and 6th  in 
DALYS (Table 2). Therefore, all available company research and BoD measures were 
compared, and trends and irregularities were the focus of the results. 
 Table 1: Company, Trial, and Participants Planned Numbers and Rankings per Disease Category 
 
 
 
Rank Disease
# of 
Companies
% of Total 
Companies Rank Disease
# of 
Trials
% of Total 
Trials Rank Disease
# of 
Participants 
Planned
% of Total 
Participants 
Planned
1 Cardiovascular disease 8 47.06% 1 Cardiovascular disease 30 14.02% 1 Cardiovascular disease 4801 28.31%
2 Mental disorders 7 41.18% 2 Malignant neoplasms 27 12.62% 2 Musculo-skeletal diseases 1657 9.77%
3 Respiratory infections 6 35.29% 3 Mental disorders 22 10.28% 3 Respiratory disease 1509 8.90%
3 Musculo-skeletal diseases 6 35.29% 4 Diabetes mellitus 20 9.35% 4 HIV/AIDS 1402 8.27%
5 Infectious/parasitic (ex HIV/AIDS) 5 29.41% 5 Respiratory disease 19 8.88% 5 Infectious/parasitic (ex HIV/AIDS) 1161 6.85%
5 Endocrine and metabolic 5 29.41% 6 Musculo-skeletal diseases 18 8.41% 6 Genito-urinary diseases 1150 6.78%
7 Malignant neoplasms 4 23.53% 7 Genito-urinary diseases 14 6.54% 7 Respiratory infections 1084 6.39%
7 Genito-urinary diseases 4 23.53% 7 HIV/AIDS 14 6.54% 8 Diabetes mellitus 902 5.32%
7 HIV/AIDS 4 23.53% 9 Infectious/parasitic (ex HIV/AIDS) 13 6.07% 9 Mental disorders 874 5.15%
10 Diabetes mellitus 3 17.65% 10 Respiratory infections 10 4.67% 10 Malignant neoplasms 729 4.30%
10 Nervous system disorders 3 17.65% 11 Nervous system disorders 9 4.21% 11 Digestive system diseases 725 4.27%
10 Respiratory disease 3 17.65% 11 Digestive system diseases 9 4.21% 12 Endocrine and metabolic 365 2.15%
10 Skin diseases 3 17.65% 13 Endocrine and metabolic 3 1.40% 13 Nervous system disorders 351 2.07%
14 Digestive system diseases 2 11.76% 14 Sense organs 2 0.93% 14 Other 200 1.18%
14 Other 2 11.76% 14 Skin diseases 2 0.93% 15 Skin diseases 51 0.30%
16 Benign neoplasms 1 5.88% 14 Other 2 0.93% 16 Maternal conditions 0 0.00%
16 Sense organs 1 5.88% 17 Maternal conditions 0 0.00% 16 Perinatal conditions 0 0.00%
18 Maternal conditions 0 0.00% 17 Perinatal conditions 0 0.00% 16 Benign neoplasms 0 0.00%
18 Perinatal conditions 0 0.00% 17 Benign neoplasms 0 0.00% 16 Sense organs 0 0.00%
18 Oral conditions 0 0.00% 17 Oral conditions 0 0.00% 16 Oral conditions 0 0.00%
Company Priorities Trial Priorities Participants Planned Priorities
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Table 2: MRC Burden of Disease Estimates, 2000 
 
k Disease Category Total % Rank Disease Category Total % Rank Disease Category Total %
HIV/AIDS 165,859 29.8 1 HIV/AIDS 4,665,410 39.0 1 HIV/AIDS 5,067,490 32.8
Cardiovascular disease 92,201 16.6 2 Inf / para excl HIV/AIDS 1,331,432 11.1 2 Inf / para excl HIV/AIDS 1,490,399 9.6
Inf / para excl HIV/AIDS 57,502 10.3 3 Intentional injuries 1,066,136 8.9 3 Unintentional injuries 1,279,304 8.3
Malignant neoplasms 41,691 7.5 4 Cardiovascular disease 917,203 7.7 4 Intentional injuries 1,210,880 7.8
Intentional injuries 38,854 7.0 5 Perinatal conditions 907,199 7.6 5 Perinatal conditions 1,055,302 6.8
Unintentional injuries 30,076 5.4 6 Unintentional injuries 802,135 6.7 6 Cardiovascular disease 1,049,599 6.8
Perinatal conditions 27,361 4.9 7 Malignant neoplasms 499,257 4.2 7 Respiratory disease 729,442 4.7
Respiratory disease 23,009 4.1 8 Respiratory infections 456,093 3.8 8 Malignant neoplasms 520,883 3.4
Respiratory infections 22,340 4.0 9 Respiratory disease 265,329 2.2 9 Respiratory infections 467,062 3.0
Diabetes mellitus 13,157 2.4 10 Diseases of digestive system 197,322 1.6 10 Nervous system disorders 421,915 2.7
Diseases of digestive system 12,617 2.3 11 Nutritional deficiencies 190,970 1.6 11 Nutritional deficiencies 403,374 2.6
Genito-urinary diseases 8,049 1.4 12 Nervous system disorders 146,742 1.2 12 Diseases of digestive system 381,426 2.5
Nervous system disorders 7,160 1.3 13 Diabetes mellitus 145,421 1.2 13 Mental disorders 304,310 2.0
Nutritional deficiencies 6,488 1.2 14 Congenital abnormalities 128,676 1.1 14 Sense organs 249,936 1.6
Congenital abnormalities 3,859 0.7 15 Genito-urinary diseases 101,980 0.9 15 Congenital abnormalities 222,283 1.4
Endocrine and metabolic 2,109 0.4 16 Maternal conditions 56,806 0.5 16 Diabetes mellitus 175,849 1.1
Maternal conditions 1,875 0.3 17 Endocrine and metabolic 39,828 0.3 17 Genito-urinary diseases 149,718 1.0
Mental disorders 838 0.2 18 Cot death 16,294 0.1 18 Maternal conditions 101,300 0.7
Benign neoplasms 744 0.1 19 Mental disorders 14,379 0.1 19 Endocrine and metabolic 75,011 0.5
Cot death 491 0.1 20 Benign neoplasms 13,763 0.1 20 Musculo-skeletal diseases 45,681 0.3
Musculo-skeletal diseases 259 0.0 21 Musculo-skeletal diseases 4,655 0.0 21 Oral conditions 21,076 0.1
Skin diseases 48 0.0 22 Skin diseases 790 0.0 22 Cot death 16,294 0.1
Sense organs -- 0.0 23 Sense organs -- 0.0 23 Skin diseases 14,529 0.1
Oral conditions -- 0.0 24 Oral conditions -- 0.0 24 Benign neoplasms 13,763 0.1
Other -- -- Other -- -- Other -- --
All causes 556,585 All causes 11,967,822 All causes 15,466,828
E: "Other" category taken out of ranking.
rce: Bradshaw et al. Inititial Burden of Disease Estimates for South Africa, 2000. Cape Town: South African Medical Research Council, 2003.
YLLs DALYs
Estimates of DEATHS, YLLs, DALYs for all persons in South Africa, 2000
Deaths
MPH Research 
Pearson and Spearman Correlation Results 
Overall, there was a moderate association between pharmaceutical company research 
and South Africa’s BoD as demonstrated by Pearson’s and Spearman’s rank correlation 
coefficients calculated for the measures of research and BoD.  Differences in correlation 
strength were observed depending on the measure of research or BoD used.   Most 
correlations were statistically significant and trends did emerge, although the small 
sample size of companies and limited number of disease categories did not result in 
statistically significant results across all correlations (Table 3). 
 
 
The range for Pearson’s correlation coefficient was 0,30 – 0,61 (p=0,01 - 0,22), median 
0,50.  The strongest Pearson’s correlation was for Participants Planned with Deaths 
(r=0,61, p=0,01), and for Sites Planned with Deaths (r=0,61, p=0,01).  The weakest 
Pearson’s correlation was for Companies with DALYs (r=0,30, p=0,22) (Table 3). 
 
The range for the Spearman’s rank correlation coefficient was 0,28 – 0,57 (p=0,01 – 
0,25), median 0,45. The strongest Spearman’s rank correlation was for Participants 
Planned with Deaths (r=0,57, p=0,01).  The weakest Spearman’s rank correlation was 
for Companies with DALYs (r=0,28, p=0,25) (Table 3). 
 
Regardless of whether Pearson’s or Spearman’s rank correlations were calculated, the 
findings were very similar in that the strongest correlations tended to be for Participants 
Planned and Enrolled, whereas the weakest correlations tended to be for Company 
Priorities.  It appeared as if companies’ actions – evidenced by the number of 
participants they have in trials – were more in line with the BoD than what the companies 
stated their priorities were. 
 
Also, across all Pearson and Spearman correlations, there was clearly a stronger 
association with Deaths, than with YLLs or DALYs.  One interpretation of this is perhaps 
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that mortality data are more readily available and therefore used in priority setting.  
Research may be less in line with YLLs and DALYs because these composite measures 
are relatively new, not available or known. 
 
Sensitivity Analysis – Correlations excluding HIV/AIDS 
Because of the high BoD for HIV/AIDS across all MRC BoD measures, further analysis 
was performed that excluded HIV/AIDS from both Pearson’s and Spearman’s rank 
calculations.  No substantial difference in the findings was apparent when HIV/AIDS was 
excluded.  When HIV/AIDS was excluded, the range for the Pearson’s correlation was 
0,28 - 0,61 (p=0,01 – 0,26), median 0,51. With HIV/AIDS excluded, the range for the 
Spearman’s rank correlation was 0,26 – 0,54 (p=0,02 – 0,29), median 0,45. These 
values are very similar to the correlations above with HIV/AIDS included (Table 3).  This 
demonstrates that with or without HIV/AIDS across both Pearson’s and Spearman’s rank 
correlations, pharmaceutical company research and South Africa’s BoD was moderately 
correlated.  
Table 3: Pearson and Spearman Correlations, including and excluding HIV/AIDS 
Measure Pearsons 
correlation
Pearsons 
p-value
Spearman 
correlation
Spearman 
p-value
Pearsons 
with HIV 
excluded
Pearsons 
with HIV 
excluded 
p-value
Spearman 
with HIV 
excluded
Spearman 
with HIV 
excluded 
p-value
Companies vs. Deaths 0.43 0.06 0.35 0.14 0.42 0.08 0.35 0.16
Companies vs. YLLs 0.42 0.07 0.31 0.20 0.41 0.09 0.30 0.23
Companies vs. DALYs 0.30 0.22 0.28 0.25 0.28 0.26 0.26 0.29
Trials vs. Deaths 0.54 0.02 0.52 0.02 0.53 0.02 0.53 0.02
Trials vs. YLLs 0.48 0.04 0.43 0.07 0.47 0.05 0.44 0.07
Trials vs. DALYs 0.52 0.02 0.43 0.06 0.52 0.03 0.44 0.06
Participants planned vs. Deaths 0.61 0.01 0.57 0.01 0.60 0.01 0.54 0.02
Participants planned vs. YLLs 0.58 0.01 0.51 0.03 0.56 0.01 0.47 0.05
Participants planned vs. DALYs 0.46 0.05 0.46 0.05 0.43 0.07 0.41 0.09
Participants enrolled vs. Deaths 0.60 0.01 0.54 0.02 0.59 0.01 0.51 0.03
Participants enrolled vs. YLLs 0.58 0.01 0.50 0.03 0.56 0.02 0.47 0.05
Participants enrolled vs. DALYs 0.45 0.06 0.45 0.05 0.42 0.08 0.41 0.09
Sites planned vs. Deaths 0.61 0.01 0.49 0.03 0.61 0.01 0.52 0.03
Sites planned vs. YLLs 0.57 0.01 0.45 0.05 0.57 0.01 0.48 0.04
Sites planned vs. DALYs 0.47 0.04 0.42 0.07 0.48 0.04 0.45 0.06
Sites final vs. Deaths 0.53 0.02 0.48 0.04 0.53 0.02 0.51 0.03
Sites final vs. YLLs 0.48 0.04 0.42 0.07 0.47 0.05 0.45 0.06
Sites final vs. DALYs 0.48 0.04 0.40 0.09 0.50 0.03 0.42 0.08
Median 0.50 0.03 0.45 0.05 0.51 0.03 0.45 0.06
BOLD statistically significant
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In summary, across all calculations for company research and BoD measures, both the 
Pearson’s and Spearman’s rank correlations moved together, with or without HIV/AIDS 
as illustrated in Figure 3 below.   This supports the consistency of the findings above 
because they are similar regardless of the correlation coefficient used. 
Figure 3: Pearson and Spearman Alignment Across all Measures, including and excluding 
HIV/AIDS 
Pearson and Spearman alignment across all BoD measures, including and excluding HIV/AIDS
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Regression Analysis - Alignment and Gaps  
Regressions of the actual values log transformed (not rankings) for all the measures of 
research and BoD were calculated (Appendix 6 – Regression calculations across all 
measures).  When the regressions were plotted in order to visualise which diseases 
were in alignment and which were not, regression graphs for those measures with both 
a Pearson’s and Spearman’s p < 0,05 revealed clear trends and formed the basis for 
identifying diseases in alignment and gaps - whereas there was too much variability to 
draw conclusions for those measures with a Pearson’s and Spearman’s of p > 0,05.   
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 Measures with both a Pearson’s and Spearman’s p < 0,05 and plotted included: 
 
- Trials vs. Deaths 
- Participants planned vs. Deaths 
- Participants planned vs. YLLs 
- Participants planned vs. DALYs 
- Participants enrolled vs. Deaths 
- Participants enrolled vs. YLLs 
- Sites planned vs. Deaths 
- Sites planned vs. YLLs 
- Sites final vs. Deaths  
 
Gaps were identified when the disease category fell far above or below the regression 
slope line.  Diseases above the regression line indicated an abundance of research.  
Diseases below the regression line suggested opportunities and need for more research.  
Alignment was identified when the disease category fell close to or on the regression 
line.  The assumption for this analysis was that the regression line represented the ideal 
level for the measure of research (e.g., number  of  companies, trials, participants per 
disease) given the BoD measure (Discussion).   
 
For example, the regression graph (Figure 4) for Participants Planned vs. Deaths 
(Pearson’s r=0,61, p=0,01 and Spearman’s r=0,58, p=0,01) shows musculo-skeletal 
diseases (R) as the greatest gap above the regression line indicating an abundance of 
research, perinatal conditions (D) as the greatest gap below the regression line 
indicating opportunities for more research, and HIV/AIDS (X) and malignant neoplasms 
(F) near the regression line indicating alignment between Participants Planned and 
Deaths.  Or, another way to interpret this regression graph is that fewer Participants 
Planned in relation to Deaths from musculo-skeletal disease (R) was anticipated by the 
regression line, and a higher number of Participants Planned was anticipated by the line 
in relation to the high number of deaths from maternal conditions (C). (Figure 4 below, 
Appendix 3 for disease categories and codes). 
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 Figure 4: Example Fitted Regression Line Graph - Participants Planned vs. Deaths 
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Aside from some moderate variation, across all regressions graphs for measures with a 
Pearson’s and Spearman’s of p < 0,05 consistent patterns of diseases in alignment and 
gaps with BoD measures were found (Appendix 7 - Regression graphs for measures 
with Pearson’s and Spearman’s p < 0,05). 
 
An abundance of research was found for: 
- Cardiovascular disease (M) 
- Mental disorders (J) 
- Musculo-skeletal disease (R)  
 
Opportunities for more research were found for: 
- Benign neoplasms (G) 
- Maternal conditions (C) 
- Oral conditions (T) 
- Perinatal diseases (D), and 
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- Sense organs (L) (except for Trials vs. Deaths and Sites vs. Deaths where it was in 
near alignment). 
 
Research in alignment was for: 
- HIV/AIDS (X) (except for Sites where it was in near alignment)  
- Infectious and parasitic diseases excluding HIV/AIDS (A) 
- Nervous system disorders (K), and 
- Skin disorders (Q).   
 
Research in near alignment was for: 
- Digestive disorders (O) (except for Trials vs. Deaths where it was in alignment) 
- Diabetes mellitus (H) (except for Trials and Participants where it was abundant) 
- Endocrine and metabolic disorders (I) (except for Trials vs. Deaths where there were 
opportunities for more research), and 
- Malignant neoplasms (F) (except for Trials vs. Deaths where it was abundant). 
 
The remaining diseases were all slightly above all regression lines, but not the farthest 
above.  This indicated that there is more research in these diseases than expected in 
relation to the BoD measures, but not a clear abundance.  These diseases include:  
- Genito-urinary diseases (P) 
- Respiratory diseases (N), and 
- Respiratory infections (B) (except for Participants Enrolled vs. Deaths and Participants 
Enrolled vs. YLLs where it was abundant). 
 
In summary, Pearson’s and Spearman’s rank correlation coefficients demonstrated that 
there was a moderate association between pharmaceutical company research and 
South Africa’s BoD.  Regression analysis determined which diseases had an abundance 
of, or opportunity for more, research, and also identified those diseases in or near 
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alignment with the country’s BoD.  Differences in association strength and degree of 
alignment were observed depending which measure of research and BoD were 
compared.  However, clear trends were evident. 
 
3.3 Qualitative Analysis of Company Priority Setting – Part Two 
 
Part Two of the study described the process and timing of how pharmaceutical 
companies decide, plus which criteria they use, to prioritise in which disease category to 
conduct research in South Africa. 
 
Process 
All 6 interviewees shared that decision-making was cooperative between themselves at 
the local company affiliate level and their main office or headquarters.  Organisationally, 
the headquarters did play a role in allocating resources and setting affiliate research 
priorities, but they were not the sole actor.  Local affiliates in South Africa fulfilled a 
decisive function that included proposing research budgets and initiating or rejecting 
research projects.  Five interviewees said the Medical Department had final say as to 
whether a trial would be conducted or not in the country.  
 
Another major theme was that South African affiliates of global companies often had to 
compete with company affiliates in other countries to “get a trial”.  Four out of the six 
interviewees mentioned they have internal lobbying presentations that they deliver to 
senior medical management which highlight the strengths of the South African affiliate 
staff and their track record for delivering quality data on time and within budget. 
 
Three interviewees raised the importance of dedicated local clinical staff in the decision-
making process.  They stated that the more clinical staff there is, the stronger the 
affiliate’s role was in the decision-making process regarding whether or not to conduct a 
trial in South Africa.  If there were little or no clinical staff, interviewees explained that 
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research was out-sourced, or temporary contract clinical staff was hired, and the affiliate 
had less of a role in the decision-making process for trials.  The questionnaire in Part 
One revealed that the majority of companies did have dedicated clinical staff (14 out of 
17 companies) and the total number of dedicated clinical staff reported for all companies 
was 146,5 people.  This supports the interview findings that decision-making was 
cooperative with headquarters as the majority of participating companies had strong 
local clinical departments. 
 
Timing 
The overall timing to conduct a clinical trial (including deciding, planning, receiving in-
country regulatory and ethics approval, implementation, and final data analysis) was 
identified by all interviewees as a critical factor in deciding whether or not to conduct a 
trial in South Africa.  They explained that molecules that were discovered years ago are 
only now coming to the trial phase and it can take up to 15 years from a drug’s discovery 
to reach patients.  Therefore, there is extraordinary pressure on industry to deliver new 
discoveries, and quality trials conducted in a timeous manner are essential. 
 
The range of time estimated by the interviewees for the decision-making process by its 
headquarters (whether or not to initiate or approve a trial in a specific country) was 3 to 6 
months.  The local decision-making by the South African Medical Directors and the 
affiliate (whether or not to accept or initiate a trial in South Africa) ranged from 1 to 6 
weeks. 
 
External regulatory approval times for clinical trials were reported to be 3 to 5 months 
from the date of submission to the South African Medicines Control Council (MCC).  All 
interviewees explained that the MCC only meets periodically so an additional 2 months 
frequently had to be added to the timeline while companies wait for the next MCC 
meeting.  Eastern Europe was often raised by interviewees as a major competitor to 
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South Africa because of their respective regulatory authorities’ ability to timeously 
approve trials and the strength of their scientific community. 
  
All interviewees recognised that both company and regulatory authorities impact the total 
timeline.  Two people mentioned that individual companies were actively trying to 
improve their own decision-making timelines, and explained that there was industry-wide 
support of the MCC’s effort to improve clinical trial approval timelines. 
 
Criteria 
Criteria for decision-making focused on feasibility, market, and environmental facilitating 
and constraining factors.  BoD also played a role, but with some caveats similar to those 
limitations identified in the literature review. 
 
Feasibility 
When asked what criteria companies use to prioritise research, feasibility concerns were 
the immediate response from all interviewees.  Feasibility included: company, affiliate, 
and external investigator expertise; the availability of participants and sites; and cost and 
time required. 
 
All companies considered in-house expertise on how to conduct clinical trials a 
facilitating factor (e.g. how to recruit patients, work with external investigators, manage 
complex data sets, and comply with ethical rules).  Companies felt that they had this 
expertise for the most part which was relevant to their decision to conduct trials because 
they could do so within their current resources.  This was supported by the questionnaire 
findings, which showed that the majority of companies in this study had dedicated 
clinical staff (14 out of 17 companies).  Furthermore, only 47 out of the 214 trials were 
contracted out (22%),  while 166 were  conducted  in-house (78%),  and 1 trial was not 
reported in the questionnaire.   
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All interviewees raised the significance of company expertise (e.g., their internal 
research infrastructure, human and financial resources, and research track record in 
specific disease areas).  One interviewee pointed out that “a company can only do trials 
if a product has made it through its discovery pipeline” which referred to the challenge of 
research not simply being about identifying a disease target, but also being successful in 
finding a promising preventive or curative intervention. 
 
Overall, interviewees praised external investigators’ scientific rigour and were proud of 
South Africa’s excellent reputation for quality research.  It was explained that external 
investigators are critical to clinical trials because they are the ones who actually see the 
participants, provide the treatment, adhere to ethical guidelines, and fill in all the 
paperwork for the company’s clinical staff to then analyse.  However, the availability of 
experienced investigators was raised by two interviewees as a growing concern.  
Potential reasons put forward were that there may be a growing amount of trials for the 
number of investigators, and that there may be fewer experienced investigators because 
many have emigrated and new ones have not yet been trained. 
 
The availability of participants and sites was reported by all to be a facilitating factor and 
was inexorably linked to the BoD in the country. Since South Africa has both “developed” 
and “developing” world diseases as noted in the literature review, there are more 
diseases that can be researched in the country, which was attractive to companies. 
 
Lastly, cost and time were raised as feasibility factors.  All interviewees said that South 
Africa was competitive against other countries when it came to costs, but there were 
concerns with regulatory approval timelines as discussed above. 
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Market 
Only a few interviewees brought up market issues unprompted.  Although when 
prompted, all interviewees expressed that marketing concerns did play a central role. 
Interviewees explained marketing opportunities were very much linked with the BoD.  
Simply put, if a disease is prevalent there is a potential market for sales.  However, four 
interviewees explained that the market is changing in South Africa to include more than 
just the 7m people with existing medical aid coverage, and reaching toward covering all 
43m citizens, through a growing private insurance market and expanding public 
coverage.  They highlighted that this expanding market is relevant to companies’ 
decisions to research in the country because it potentially provides a better return on 
their investment with greater sales opportunities in both the private and public markets. 
 
Furthermore, it was elaborated upon by one interviewee that the market size is also a 
function of whether the patient, government or private insurance-based medical scheme 
is willing and able to pay.  It was explained that purchasers were reluctant to pay for life-
enhancing medicines (e.g., urinary incontinence) because they tended to focus only on 
those diseases with high mortality where they can see an immediate benefit from the 
medicine.  Also, treatments for chronic diseases (e.g., hypertension) encountered 
various hurdles, such as restrictive treatment guidelines, prescribing limitations, pre-
authorisation by the payer, and exclusions from formularies based only on immediate 
cost and not long-term cost-benefit analysis.  These obstacles also played a role in 
companies’ decision on how large the potential market may be, and therefore whether to 
conduct a trial in South Africa or not. 
 
Three interviewees reported that if a low marketing opportunity were identified, yet the 
BoD was high, their headquarters would consider supporting local trials, both financially 
and with human resources (e.g., HIV/AIDS trials).  
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Results from the questionnaire illustrated that companies determined they do have a 
market for most of their products in trials.   The majority of trials (140 out of 214, 65%) 
were for products that companies were seeking registration for in South Africa, 53 trials 
(25%) were with products already registered, and 13 trials (6%) were for products not 
seeking registration.  New MCC trial approval criteria introduced in 2000 may have 
contributed to the high number of trials for products seeking or already having 
registration because the MCC requires companies to state whether they are seeking 
local registration, why the product is needed, and how it will benefit South Africans (MCC 
2003a).  However, interviewees had the impression that these criteria were not 
consistently applied, and more importantly, felt that companies sought registration for 
their products because of the potential market, and not because of MCC requirements. 
 
Environment 
The importance of a pro-research environment was raised by all interviewees.  In 
addition to the feasibility factors outlined above, interviewees identified the need for a 
strong scientific infrastructure that supplies researchers and services, and a supportive 
government that attracts and fosters research initiatives.  Although interviewees did not 
specifically comment whether the scientific infrastructure or government support was a 
facilitating or constraining factor, they alluded that these factors could be part of the 
reason why companies were not pursuing pre-clinical research (3 out of 17 companies 
reported pre-clinical work in the questionnaire) and that most companies focused on 
later stage Phase 3 trials (Table 4 and Definitions).  It was explained that discovery 
research (pre-clinical and early phase research) was highly dependent on well-trained 
scientists and adequate facilities, as well as the enforcement of strong intellectual 
property laws to protect new discoveries.  The fact that companies are not investing in 
discovery research or early phase clinical trials is perhaps an indication that there is 
potential to attract this type of research to South Africa.       
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Table 4: Total Phases of Trials Reported 
# of Phase 1 
Trials
# of Phase 2 
Trials
# of Phase 3 
Trials
# of Phase 4 
Trials Total Trials
# 12 42 141 19 214
% 5.61% 19.63% 65.89% 8.88%
 
Interviewees also suggested that environmental factors may be the reason why this 
study found the overall number of trials was declining (Figure 5).  It is unclear what 
factor, or combination thereof, is specifically driving this trend and further analysis of this 
is outside the scope of this study. 
Figure 5: Declining Number of Trials 
Trend in # of Trials (2000-2003)
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Two interviewees also mentioned that an important facilitating environmental factor was 
the international recognition of the South African MCC because trials conducted in South 
Africa were eligible for approval in the European Union and the United States.  This 
enabled companies to include South Africa in their global research initiatives. 
 
A constraining environmental factor identified was a generally negative attitude toward 
pharmaceutical research in the country.  Specifically, interviewees raised concerns that 
negative conceptions about industry research, such as assumptions about using people 
as ‘guinea pigs’ in trials and ‘industry only caring about profits’ (quotes from interviews) 
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undermined the benefits of research.  They listed these as creating life-saving and life-
enhancing medicines for unmet medical needs, building and supporting the research 
infrastructure in the country through creating jobs and attracting foreign investment, 
linking South Africa with the global research community, and providing access to new 
treatments through trials and post-trial care which otherwise would be inaccessible. 
 
Burden of Disease  
All interviewees said that the use of BoD measures (Deaths, YLLs, DALYs or other 
measures such as prevalence and incidence) was part of their decision-making process, 
but not a sole criterion.  As described above, it was explained that other factors such as 
feasibility, market and environment played a crucial role, and are inexorably linked to 
BoD.  For example, if the BoD is significant, so will be the number of participants for 
trials, as will be the potential market. 
 
Furthermore, three interviewees highlighted dangers of focusing just on BoD as a 
criterion for research. Smaller companies were especially concerned about using BoD 
as a sole criterion because they felt that they should not be penalized if they do not 
happen to have expertise in an area of the greatest burden.  One interviewee said, “Not 
all companies can specialise in the top burdens, and we all need to find our niche.  We 
don’t want to be penalised for specialising”.   
 
Another interviewee raised similar concerns for people living with orphan diseases 
(those diseases that are not common, e.g., growth hormone deficiency) or a disease 
deemed to be of lower burden (e.g., glaucoma).  The interviewee said that if 
pharmaceutical research were targeted to only those diseases with the greatest burden, 
those people who do not have a high-ranking disease would be at a disadvantage. 
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The majority of interviewees raised concerns about maintaining the competitiveness of 
South African researchers if research only focused on top disease burdens.  An example 
was given that South Africa’s globally recognised leadership in laser eye surgery would 
have never happened if public and private researchers were restricted to investigating 
only top burdens of disease.  Furthermore, interviewees said that delaying or not 
approving trials for low burdens of disease or life-enhancing drugs would limit South 
African investigators’ ability to participate in the international research community which 
might be focused on diseases that may not be as prevalent in South Africa yet.  It was 
suggested that South African researchers in these fields would become frustrated and 
pursue their work elsewhere. 
 
Lastly, four interviewees suggested that using BoD as a core criterion for prioritising 
pharmaceutical research was short-sighted.  They explained that today’s available BoD 
data reflects yesterday’s diseases due to the time lag in data collection, and research 
should not focus only on today’s problems, but anticipate what tomorrow’s future health 
challenges will be.  One interviewee said, “in 5 years down the line hopefully we can look 
at other diseases [besides HIV/TB].  The prevalence and incidence of emerging 
diseases will change.  In '98, the focus on breast cancer was huge.   Now it's under 
control.  Today's issue is HIV. Tomorrow who knows?”  Furthermore, all interviewees 
expressed that pharmaceutical research extends beyond just meeting a country’s BoD to 
developing the country’s research capacities and international competitiveness.  
 
In summary, the qualitative interviews revealed that feasibility, market forces and overall 
research environment issues were all important in the prioritisation process for 
companies.  Also, the BoD, although an important criterion, was not the sole criterion, 
and there were concerns with relying on it as an ideal benchmark for research in the 
country because of its limitations. 
MPH Research Report: J Hoerter 0310496H   45
 3.4 Link Between Quantitative and Qualitative Results 
 
The quantitative results of Part One of this study that identified gaps and alignment 
between pharmaceutical company research and South Africa’s BoD are best interpreted 
with the qualitative findings of Part Two that explored the process and criteria companies 
use to decide their research priorities.  
 
Gap areas that were identified may have been indicative of other factors aside from BoD 
playing a role in companies’ decision-making process. For example, the abundance of 
research in cardiovascular disease, mental disorders and musculo-skeletal disease 
appeared to be in excess of the MRC’s current BoD measures.  If BoD were the sole 
comparator for the “right” amount of research, one conclusion could be that less 
research should be devoted to these diseases.  However, based on the interviews, 
companies do not make decisions purely on the basis of current BoD.  Rather, it seems 
likely that these diseases were chosen because they were more feasible to conduct 
trials, the market was more promising, and companies anticipated the future BoD to 
include these diseases. 
 
For those gap areas with opportunities for more research, such as perinatal diseases 
and maternal conditions, these diseases appeared to be grossly under the MRC’s 
current BoD measures.  Again, if BoD were used as the sole “gold standard”, one 
conclusion could be that more research should be devoted to these diseases.  Or, 
another conclusion given the multi-faceted nature of health priority setting arising from 
the interviews could be that industry’s lack of research in these areas might be a 
reflection of difficult feasibility issues such as access to participants for clinical trials, or 
environmental considerations such as the prominence of other determinants of poor 
health for these disease burdens such as nutrition and sanitation.  Or, these gaps could 
be a result of industry’s perceived lack of market for maternal and perinatal conditions. 
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 For areas in alignment, such as HIV/AIDS and infectious and parasitic diseases 
(excluding HIV), they appeared to be on target with the MRC’s current BoD measures.  
Therefore, one could conclude when using BoD as a sole criterion, that the “right” 
amount of research is being conducted in these diseases.  However, since the 
interviews showed that companies do not look solely at BoD, any alignment between 
research and BoD may be happenstance and the feasibility, market and environmental 
issues may have been such  that  they encouraged companies  to conduct  trials  in the 
these specific burdens of disease.  Facilitating factors for research that these diseases in 
alignment shared in common merit further exploration because these characteristics 
could then be used encourage private pharmaceutical company research in other 
diseases of need. 
 
In conclusion, although the quantitative findings revealed alignment and gaps between 
pharmaceutical company research and South Africa’s BoD, the interviews supported the 
literature review findings that health priority setting is multi-faceted and not one criterion, 
such as BoD, is solely relied upon.  Therefore, it is important to recognise the limitations 
of relying on BoD measures as a “gold standard” comparator for pharmaceutical 
company research.  However, the results of this study remain instructive pending the 
development of other comparators and methodologies.  Furthermore, the qualitative 
results of this study may point to policy actions that can be taken to better leverage 
private pharmaceutical company research to meet public health needs. 
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4.0 Discussion  
 
This study reveals the complexities of encouraging pharmaceutical company research in 
South Africa in areas of health need by blending a quantitative analysis which identified 
alignment and gaps between pharmaceutical research and the country’s BoD, with a 
qualitative description of the process and criteria companies use to prioritise their 
research.  This two-fold approach enables a more robust interpretation of the results that 
adds to the existing body of knowledge on health research priority setting.  Furthermore, 
the implications of these findings can impact current policy and practice, whilst 
recognising the study’s limitations. 
 
4.1 Results in Relation to Existing Literature 
 
Knowledge of pharmaceutical company research priorities 
Based on trends found in the international literature, it was anticipated that 
pharmaceutical research in South Africa would not be in line with the country’s BoD as 
was found in other countries (Comanor 1996; Michaud and Murray 1996; MSF/DND 
Working Group 2002; Yamey 2002).  However, this study reveals that overall there is 
moderate alignment between pharmaceutical company research in South Africa and the 
country’s BoD.   Furthermore, the findings go beyond existing aggregate studies and 
specifically identify diseases in alignment and gaps with the country’s BoD.  It is 
recognised that this study did not capture research outside of the country; however, this 
study does provide a previously unknown baseline and is an important step toward 
leveraging private pharmaceutical company research in South Africa to meet public 
health needs.   
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 Understanding priority setting processes 
The first key issue identified in the literature review, which was the need to recognise 
various stakeholder objectives when examining priority setting, was not specifically 
raised in the interviews.  However, it is important to point out that there were two distinct 
perspectives on this study that emerged anecdotally prior to its start.  Most public health 
and government experts I informally consulted assumed this study would prove the 
industry was not focusing on needs of South Africa, whereas most industry people 
thought they do focus on the needs of the country - otherwise they would not have a 
business.  Although the literature also suggested that public health objectives to reduce 
overall BoD and private industry objectives to provide medicines to a consumer market 
may clash, the results show that their objectives can be complementary.  For example, 
the company research priorities in alignment with South Africa’s BoD, such as HIV/AIDS 
and infectious diseases, informs us that these diseases are priorities for both parties.  
However, this study reveals that the rationale for choosing these targets may differ.  
Public health officials may deem it a health need based on BoD, while companies may 
deem it a research priority where trials are feasible, the market is attractive and the 
overall environment for research is supportive.  For those areas of company research 
that are not in alignment with the BoD, such as cardiovascular disease where research 
is in abundance, or maternal conditions where there are opportunities for more research, 
this study goes beyond existing literature.  This study not only points out these gaps, but 
provides policy makers additional insight on ways to encourage research in diseases of 
need that incorporate companies’ objectives and the criteria they use for priority setting 
so as to maximise private company research to benefit public health. 
 
The second key issue identified in the literature review, namely that health priority setting 
is complex and multi-faceted, was clearly supported by the findings of this study which 
revealed the importance of feasibility, market, environmental issues and BoD in 
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company decision making.  However, these findings differ from some assumptions 
identified in the literature review that stated research was primarily driven by 
headquarters marketing personnel and global profit strategies (MSF/DND Working 
Group 2002; Resnik 2003).  Specifically, feasibility and environmental issues tended to 
dominate the interviews more so than market influences. This was perhaps because 
Medical Directors were interviewed and they came from the medical perspective of 
practically getting the trials done.  This complex set of criteria furthers our understanding 
of why some company research priorities are in alignment with disease burdens and 
others are not because it is apparent that there are more factors involved in priority 
setting than just BoD.  However, what is not well known is the weighted importance of 
the various factors in decision-making, which was outside the scope of this study. 
 
Methodological aspects 
The third key issue that emerged from the literature was the limitations of relying solely 
on BoD as a comparative indicator for pharmaceutical company research.  Similar 
concerns were echoed in this study’s findings and include: 
  
• Medicines are not the only solution to reducing BoD 
This study’s major assumption is that medicines reduce the BoD.  As doctors and 
patients alike may attest, pharmaceuticals can play an important role, but the 
interviewees pointed out that medicines are not the only solution to reducing BoD.  
Gilbert also raised this concept in her article about other determinants of health that 
may have an even stronger influence on BoD such as environmental pollution that 
can aggravate asthma, social inequalities that can lead to increased HIV/AIDS rates, 
gender inequalities that can result in rape, economic stress that can induce high 
blood pressure, and crime that can multiply injuries (Gilbert, Selikow, Walker 2002).  
Bradshaw et al advocated, “all role players, including government, pharmaceuticals, 
business, NGOs and the community need to give urgent attention to this [burden of 
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disease]” (Bradshaw et al 2003a, xi) in recognition that one intervention alone can 
not effectively reduce a country’s burden of disease.  Furthermore, Mrazek and 
Mossialos pointed out that, “stimulating research and development for neglected 
diseases is important as part of a wider long-term public health strategy and must be 
addressed simultaneously with resolving more immediate problems of access to 
medicines and health system sustainability in less developed countries”  (Mrazek 
and Mossialos 2003, 75). 
 
• Changing burdens of disease 
This study’s findings also reflected Varmus’ concern found in the literature that policy 
makers should not just focus on today’s health challenges, but need to consider 
future burdens (Varmus 1999).   Interviewees’ mention of the 15-year lag time 
between drug discovery and delivery of a new medicine to patients is an indication 
that companies focus their research on tomorrow’s diseases, and not just today’s.  
Furthermore, given the unpredictability of discoveries, one never knows what 
findings today in an “unimportant” area (e.g. toenail fungus) can impact a very 
serious disease tomorrow.  Moreover, the abundant areas of research identified in 
this study may be the highest burden of disease in the future (e.g., growing 
cardiovascular disease needs). Therefore, given that BoD measures are calculated 
from historical data, they may neglect to anticipate what tomorrow’s health problems 
will be. 
 
The changing BoD pattern is especially relevant for South Africa.  Not only does 
South Africa face developed and developing world health challenges (Bradshaw et al 
2003b, 1), it is undergoing an “epidemiological transition [that] includes changes in 
the cause of death patterns and overall changes in health and disease that occur 
during socio-economic transformation” (Bradshaw et al 2003a, 2).  For example, “it is 
estimated that the South African population 60 years and older was 2.9 million in 
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2000, constituting 6.4% of the total population.  These figures are estimated to 
increase to 3.95 million and 8.4% in 2010” (Joubert, Nannan, Bradshaw 2003, 155).  
Therefore, it would be short-sighted to limit scientific discovery to only what is 
deemed important today. 
 
• Unintended consequences of relying on BoD 
The interviews also revealed two limitations of relying on BoD that were not found in 
the literature. First, all companies do not have the capacity to specialise in all the top 
disease priorities.  This was reflected by the concerns of smaller companies that did 
not want to be penalised or hindered from conducting research in their niche areas 
because they do not happen to reflect the country’s BoD.  Furthermore, having all 
companies focus on top BoD would not be very efficient because each would be 
duplicating the other’s efforts.  Second, the interviewees pointed out that if 
pharmaceutical research were targeted at only those diseases with the greatest 
burden, those people who do not have a high-ranking disease would be at a 
disadvantage.  This is intuitive because if something is chosen as a priority, this 
means something else is not – which is the underlying challenge of priority setting 
because not all diseases can be priorities.   
 
The fourth key issue raised in the literature was the need to compare multiple measures 
of research and BoD with a variety of statistical tools in order to have a more complete 
representation of their relationship.  Otherwise a study’s findings could be misleading.  
Therefore, this study intentionally expanded upon previous methodologies found in the 
literature in that it deliberately examined multiple measures of research and BoD with 
statistical analysis of both rankings (Spearman’s correlation coefficient) and actual 
values (Pearson’s correlation coefficient and regressions).  Furthermore, this study 
generated new measures of research according to company, trial, participant and site 
priorities.  These measures broke away from the traditional study design that focused on 
the use of expenditure as a measure of company research (PMA 1997, Wits Health 
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Consortium 2000, Department of Science and Technology 2003).  Firstly, this was 
because expenditure data per disease was difficult to access, and secondly, it was 
decided that these unique measures were a better indication of company research 
activity.  This study was also the first known comparative analysis that used all three of 
the MRC’s new BoD measures (Deaths, YLLs and DALYs). These methodological 
advances and knowledge gained through this exercise may enable other researchers to 
conduct similar analyses to compare BoD with other areas of health, such as numbers of 
medical personnel or patient access to care. 
 
4.2 Impact on Policy and Practice 
This study’s findings can enable both public and private decision-makers to generate 
realistic policies to encourage pharmaceutical company research in areas of need.  The 
results indicate that strategies that are beneficial to public, private and other 
stakeholders are the most feasible and cooperation among the sectors is vital for all 
parties to meet their respective objectives.  For example, companies need public health 
officials to identify areas of unmet medical need, create sustainable health care systems 
to deliver medicines, and foster favourable research environments.  Public health 
officials need companies to discover and develop new medicines to prevent or treat 
unmet medical needs and provide them at accessible prices on both public and private 
markets.  The multi-faceted nature of company research priority setting described in this 
study complicates policy making because there is no simple framework that can be 
applied.  Therefore, a combination of strategies may be necessary. 
 
First of all, the results of this study show that in order to leverage private pharmaceutical 
company research to benefit public health, companies need to be enticed to make 
choices that are good for both their business and public health.  Directing research 
toward areas of need by either asserting that companies should be benevolent (Isaakidis 
et al 2002), or hindering or preventing companies from researching what they choose 
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may have the opposite effect and drive research away from diseases of need or out of 
the country.  This sentiment was echoed by the former head of the US National Institutes 
of Health (NIH) who objected to US Congressional directives to guide research priorities 
in the  public sector because of  the multi-faceted nature of  allocating research  dollars 
(Varmus 1997).  One could assume that such mandates would be highly controversial in 
the private sector too because as the interviews revealed, other factors such as 
feasibility, market and the overall environment are important to industry decision making.  
Furthermore, the study’s findings show that South Africa competes with other countries 
for industry research and such a punitive approach to increasing research would 
potentially have negative consequences and reduce research in priority disease areas 
because companies can conduct their research elsewhere. 
 
Secondly, a combination of “push” and “pull” strategies aimed at companies, and 
infrastructure development aimed at countries, emerged from the international literature 
as the most feasible way to stimulate pharmaceutical research in areas of need.  Widdus 
explained, “Push interventions to lower the costs and risk of product development for 
industry, with pull interventions providing economic and market incentives, and the 
creation of infrastructures allowing products to be put into use” (Widdus 2001, 713).  
Reich further outlined four common “types of fixes” for when there is a need for more 
research in unmet medical needs: 1) public subsidies through national and international 
organisations, 2) new public-private partnerships which combine the skills of private 
researchers with public health experts, 3) protection of product patents in developing 
countries to create incentives for the private sector, and 4) the creation of ‘purchase 
funds’ or guaranteed markets for future products” (Reich 2000, 1980).  Other authors 
made additional infrastructure oriented suggestions such as the creation of capacity-
building programmes for researchers, government funding of basic research, 
government policy coordination among trade, health, finance, and justice, and 
development of a sustainable health care system.  Other “pull” suggestions were the 
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creation of markets with tiered pricing, and rewards of patent-life extension in a 
“Western” market for the development of a drug for a neglected disease  (Erill 1998; 
Resnik 2003; Webber 2003; Wolffers, Adjei, van der Drift 1998).   
 
This push/pull approach incorporates strategies that would not only assist in attracting 
research to high burdens of disease which hopefully would result in more prevention and 
treatment options, but would also support other public health objectives such as 
improving access to health care and sustaining scientific and academic infrastructures.  
These strategies would also meet the private sector objective to provide medicines to a 
larger market because companies would better meet the needs of more people, while at 
the same time the strategies would enhance the feasibility and timing of trials and foster 
an environment that welcomes clinical research.     
 
However, a potential conflict emerges between pharmaceutical company research and a 
country’s burden of disease when strategies cannot be identified that would make 
clinical trials more feasible, the market more attractive, or the overall research 
environment supportive enough to attract company research on specific disease.  In this 
case, it may be necessary for policy makers to tap into other sources of research such 
as government or non-governmental organisations.  For example, as recognised by the 
leaders at the US National Institutes of Health, “complementary activities in other 
agencies…[and] in the pharmaceutical and biotechnology industries…may favor the 
expenditure of NIH dollars on relatively rare diseases, with low values for the BoD, as 
measured in terms of disability-adjusted life-years, for which there is little incentive for 
research and development in the private sector” (Varmus 1999, 1914). In Gross et al’s 
study comparing NIH funding with BoD in the US, they further elaborated that “although 
research performed by industry may be distinct from NIH-funded research in a number 
of ways, it is important for policy makers to consider these substantial efforts when 
allocating [public] funds” (Gross et al 1999, 1885-1886).  This was evidently in 
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recognition that company research can be leveraged for certain diseases, and where 
they cannot, other resources need to be employed.  However, regardless of whether for-
profit companies, government, or non-profit organisations conduct research, the 
feasibility of trials, the source of funding (be it profit, taxes or donations), and an overall 
supportive research environment still needs to be in place. 
 
The literature revealed that many countries have implemented specific programmes to 
encourage pharmaceutical research such as the European Union’s Sixth Framework 
Programme for Research and Technological Development (2002-2006) (Bjerrum 2002).  
Other incentives programmes have been created in Japan, Australia, India, Spain, 
China, Ukraine, Ireland, United Kingdom and South Korea (SCRIP 2003a-e, 2001a-b, 
2000a-b).   
 
 
These efforts to foster pharmaceutical research raise two questions.  First, why would a 
country be interested in persuading companies to conduct research in the country? And, 
second, does research on country-relevant diseases need to take place in the country 
when such research could theoretically take place anywhere?  Webber proposed an 
answer to the first question and outlined “benefits of pharma R&D [research and 
development] for host countries” which include: 
 
• Establishment of high value-added, high technology sector; industry 
diversification 
• Contribution to economic growth and trade surplus 
• International credibility and a raised country profile as host to high technology 
investment across a broader front 
• Development and commercialization of public sector research 
• Increase potential inward investment and joint ventures 
• Better access to modern technology and information and technology transfer 
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• High quality jobs – deployment of graduates/PhDs from university 
• Reduce or limit brain drain 
• Improved healthcare through access to newer medicines 
• Country capacity to understand and use state-of-the-art science, and maintain 
public confidence 
• Tackle country-specific disease/medical problems 
• Contribution to global public good”  
(Webber 2003, 9-10) 
 
With regard to the second question, Webber points out the benefit of being able to 
“tackle country-specific diseases, (2003, 10)” but he does not limit a country’s research 
scope to country-relevant diseases.  Webber recognises that the infrastructure and 
capacity building benefits of research extend well beyond just meeting a local health 
need, and attracting any research can improve the overall social, political, economic and 
social climate of a country. 
 
On the other hand, Comanor argued that, “Research and innovation may be influenced 
by their geographic location to the detriment of patients and consumers in lands where 
these efforts are not undertaken” (1996, 205). This thinking supports the concept that 
one should attract in-country research on country-relevant diseases with the assumption 
that if a country does not research country-relevant diseases, there is no guarantee that 
somebody else will.  This is evidenced by the numerous multi-country and intersectoral 
partnership initiatives that have been launched with the aim of developing and providing 
drugs for neglected diseases such as the new Drugs for Neglected Diseases Initiative 
(DNDI). (Nelson 2003; Butler 2002; SCRIP 2002; Gelband and Trouiller 2002; Mrazek 
and Mossialos 2003).  Although no single country is driving the process, the trials for 
these new drugs are predominantly in countries affected by neglected diseases because 
that is where the patients, and respective burden of disease, are located. 
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Therefore, there is not clear agreement on whether there should be a link between in-
country research and a country’s burden of disease.  However, as discussed in the 
literature review, many recent studies did examine in-country research in relation to a 
country’s burden of disease as a starting point for priority setting, which informed the 
design of this study.  With respect to South Africa, the country is unique because it’s 
“own diseases” are both of the developing and developed world and its disease profile is 
changing (as noted in the literature review).  It also has an excellent foundation and 
capacity for research.   As a result, South Africa is perhaps in a good position to assume 
a leadership role in clinical research on its country-relevant diseases which would not 
only benefit developing countries on the African continent and beyond, but also 
developed countries.  Furthermore, research on country-relevant diseases may allow for 
the further advancement of local expertise in diseases that affect South Africans, and 
therefore potentially improve the local health care system’s ability to treat such diseases.  
However, this is not to say that research on country-relevant diseases should be to the 
exclusion of other research.  Given the potential benefits of any research outlined by 
Webber above, South Africa’s changing disease profile, and its promising leadership 
position in global clinical research, it would be advantageous for the country to attract as 
much research as it could.  If, then, South Africa would like to leverage pharmaceutical 
company in-country research for its diseases of need, this study provides a starting point 
for that discussion. 
 
South Africa has recognised these opportunities and has taken steps to encourage 
pharmaceutical research.  The National Drug Policy for South Africa stated that drug 
research and development is a priority. “Research aimed at alleviating common 
diseases and complaints will be encouraged, eg the development of new, less toxic, 
more effective and more stable drugs and vaccines for existing conditions” (DoH 1996, 
24).  A pharmaceutical investment study commissioned by the Department of Trade and 
industry (DTI) sought to describe facilitating and constraining factors for pharmaceutical 
MPH Research Report: J Hoerter 0310496H   58
research, development and manufacturing in the country and further assessed South 
Africa’s international competitiveness (CMCS 2001).  It was also estimated by DTI that 
South Africa currently attracts R1 billion/year in foreign capital investment/year for 
pharmaceutical clinical research, and has the capacity for R3,6 billion (Bisseker 2002, 
1).  South Africa’s excellent research track record, especially for pharmaceutical 
company clinical trials, has been recognised internationally, and its “solid reputation for 
clean data on time at competitive prices has made it a comfortable place for 
multinationals to conduct trials for the past two decades” (Bisseker 2002, 1).  
Furthermore, the country was described as well positioned for research because of its 
intellectual capacity, competency in medical practice, academic investigators, availability 
of participants, favourable local trial costs, and solid long-term relationships between 
sponsoring companies, academic institutions, private investigators, and the Medicines 
Control Council (MCC) (Haus 2001b, 49).  Attracting more research to South Africa and 
supporting current research would only further enhance South Africa’s research 
expertise. 
 
However, there were concerns both in the interviews and literature that South Africa is 
losing its competitive edge in pharmaceutical research.  The following reasons were 
suggested: delays in clinical trial approval timelines and mismanagement of applications 
due to an under-resourced Medicines Control Council (MCC), a brain drain of company 
and academic experts, threatened intellectual property protection and proposed pricing 
regulations, a crumbling tertiary sector, negative sentiments toward research such as 
people being used as ‘guinea pigs’ for profiteering multinationals which resulted in mixed 
messages about welcoming research in the country, a fragile political situation in 
neighbouring countries, and international concerns over the South African government’s 
position on the causality of AIDS (interviews; Bisseker 2002; Haus 2001b). 
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Responses to these concerns in the interviews and literature also reflected the need for 
a push/pull approach for South Africa aimed at stimulating trade policies to benefit 
pharmaceutical research.   Suggestions focused on the need for greater cooperation 
amongst all stakeholders and the call for the creation of a forum where all government, 
private and academic parties can work together to devise a strategy for attracting clinical 
research to South Africa (Bisseker 2002; Haus 2001b).  Haus further suggested that 
better relations between company sponsors and investigators could be forged, and 
company philanthropy could be directed into governmental, parastatal and university 
organisations in return for their support (Haus 2001a, 5).  The interviewees also 
recognised that the MCC has made efforts to improve their approval timelines, the 
Minister of Trade and Industry publicly announced that South Africa welcomes clinical 
trials, and the government has made substantial efforts to expand access to health care 
in both the public and private markets.  What is not known is how South Africa’s efforts 
and current research environment compare with other countries which may provide more 
insight on ways to further encourage pharmaceutical company research on diseases 
important to South Africa as opposed to other countries’ disease needs. 
 
Lastly, any discussion about stimulating clinical research is not complete without 
addressing yet another, and extremely important, parameter - ways to ensure research 
is ethical.  Much of the literature found on clinical research by pharmaceutical companies 
centred on ethics and pointed out the need for companies to gain adequate informed 
consent from participants, ethically design studies, and ensure that trials are related to 
the country’s health needs. Benatar went further to advocate that more attention should 
also be given to the distribution of risks/harm and benefits of trials to individuals and 
communities (Benatar 2002).  Ethics relating to clinical research were outside of the 
scope of this study, however, policy makers need to include ethics as part of any 
strategy to stimulate research. 
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In summary, the combination of push/pull strategies, and the experiences of other 
countries and South Africa, and the importance of ethics are all indicative of the multi-
faceted nature of priority setting and the need for a flexible approach to maximise private 
company research to benefit public health. 
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4.3 Impact of Study’s Limitations on Conclusions 
 
In addition to the limitations identified in the study design, other aspects that impact the 
interpretation and conclusions of this study merit further discussion.   
 
The core limitation of this study is that it compares pharmaceutical research only with 
BoD measures – aside from the concerns identified the literature and interviews 
regarding the use of BoD measures as a sole comparator.  This was because BoD 
measures were the first comprehensive calculation of health need for South Africa as 
they included both morbidity and mortality, and they were the most realistic option to use 
as the baseline for this study because they were readily available.  Moreover, relying on 
BoD was appropriate because the research question was framed in terms of the 
relationship between research and BoD.  However, when interpreting the conclusions of 
this study it is essential to recognise that: 
 
• Burden of disease measures are not 100% accurate.   
The MRC raised similar concerns with its own BoD calculations as were found in 
the literature (Section 1.6).  They cited the lack of reliable mortality data, a high 
proportion of ill-defined causes (15%), problematic cause of injury estimates, 
variations in mortality between subpopulations, age weighting and discounting 
values not specific to South Africa, and the impact of the aggregation levels used 
as critical limitations with the measures (Bradshaw et al 2003a, 53-54).  
However, they stressed that, “while these estimates of YLDs and DALYs for 
South Africa should not be considered definitive, they do illustrate the importance 
of including non-fatal outcomes when ranking diseases and conditions” 
(Bradshaw et al 2003a, x).  Therefore, while there are some inherent limitations 
in BoD measures which lie outside of this study design’s control, it is critical to 
interpret the results of this study within the context of South Africa’s unique 
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health care challenges that span communicable and non-communicable 
diseases, HIV/AIDS and injuries. 
 
• Pharmaceutical research can impact more than one disease burden. 
The conclusions of this study are limited to the diseases categories used by the 
MRC.  As noted in the study design (Section 2.4), the MRC’s BoD taxonomy 
included diseases that were not amenable to pharmaceutical intervention, and 
were therefore excluded for this study.  Nor did the taxonomy allow companies to 
indicate when a trial could impact more than one disease burden.  For example, 
trials for sepsis could have been classified under perinatal, maternal or oral 
conditions, but as only one disease category could be chosen, it was classified 
under infectious and parasitic diseases (excluding HIV/AIDS).  Furthermore, 
maternal conditions such as pregnancy-induced hypertension could have been 
treated with pharmaceuticals in trials that were classified in other categories 
(such as cardiovascular disease). Therefore, this may have been the reason why 
perinatal, maternal and oral conditions ranked low in the analysis while 
cardiovascular and infectious diseases (excluding HIV/AIDS) ranked high.  
Lastly, many disease categories are interlinked, such as diabetes being a risk 
factor for cardiovascular disease, so the classification is not always exclusive.  
These categorisations limit the findings of this study because there may have 
been under- or over-reporting of diseases. Aside from these limitations, the MRC 
categories were used because they allowed a direct comparison with the MRC 
BoD measures and do provide a baseline. 
 
• Priority setting is multi-faceted and burden of disease is only one of many factors. 
Although this is a key finding  in both  the  literature  review  and  interviews, it  is 
important to highlight the point  that  BoD  is only one  of many factors  that are 
considered when priority setting for health.  Therefore, in recognition that priority 
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setting is multi-faceted, it is essential to situate Part One of this study, which did 
not examine the association between research and any factors other than BoD, 
within the findings of Part Two, which identified other parameters that companies 
consider when setting priorities for their research (e.g., feasibility, market, and 
environment).  
 
Furthermore, because this study only focused on research conducted in South Africa, a 
more complete analysis of research that benefits South Africans would require further 
examination of company research priorities at a global level in comparison with South 
Africa’s health need. 
 
Other limitations of this study that are on a more technical note include: 
 
• Impact of inclusion/exclusion criteria 
Because private pharmaceutical companies conducting clinical research on new 
medicines in South Africa were the specific population of focus for this study, it is 
inappropriate to extrapolate these results to their research outside of South 
Africa, or to pharmaceutical research conducted by others such as generic 
companies which are testing existing medicines or non-profit or government 
research. 
 
• Interpretation of number of participants and sites 
The number of participants planned and enrolled, and number of sites planned 
and final per trial were measured as a surrogate indicator of the magnitude of 
research by companies.  However, the number of participants and sites does not 
always reflect the level of commitment of a company to a disease or trial, 
because these numbers are driven by statistical requirements for sample size.  
For  example,  if  the trial were global,  it may  have had a very large  number of 
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participants world-wide, with a small number of participants in South Africa, and a 
higher sample size was not needed.  In this case, a small sample size may not 
mean the trial was of low importance, but may just mean the  company found 
sufficient  patient  numbers elsewhere.   Also, it is a value judgment as to what 
constitutes a “big” or “small” number of participants or sites.  For example, 5 sites 
for ulcerative colitis may be a big trial given the low disease prevalence, and 5 
sites for HIV/AIDS may be a small trial given the high public importance of the 
disease. This same issue was identified by Isaakidis et al where it was found that 
“trials can vary substantially in size and importance” and may not accurately 
reflect the amount of emphasis given to a specific disease category (Isaakidis et 
al 2002, 3). Therefore, the number of participants and sites is illustrative in this 
study, but not an absolute indication of the magnitude of company research. 
 
• Degree of association between research and burden of disease depends on 
which measure of research (e.g., company, trial, participant or site priorities) and 
which burden of disease measure (e.g., Deaths, YLLs or DALYs) was examined, 
and which comparative statistical tool (Spearman’s, Pearson’s or regressions) 
was used. 
It is important to emphasise that which measure of research, BoD, and statistical 
tool have been used need to be specified when interpreting the results. 
Otherwise, as noted by Gross et al (1999) the results could be misinterpreted or 
selectively used by stakeholders to highlight their own point of view. This 
potential problem was  minimised by  examining  multiple  measures of research 
and all three available BoD measures, then reporting the trends and irregularities 
across all statistical approaches used for this study. 
MPH Research Report: J Hoerter 0310496H   65
 In summary, this study clarifies previously unknown company priorities, impacts on 
policy and practice for priority setting by pointing out the need to recognise different 
stakeholder objectives and incorporate multi-faceted parameters into strategies to 
stimulate research, and acknowledges the limitations of relying solely on BoD as a 
comparator for research needs.  Specifically, it is clear that BoD is not a ‘gold standard’ 
for comparing research to health needs, but rather it is only one aspect of health 
research priority setting.  Therefore, the results of this study must be interpreted within 
the complex nature of health priority setting. 
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 5.0 Conclusions and Recommendations 
 
Pharmaceutical company research in South Africa is moderately associated with the 
BoD of the country, and the feasibility of clinical trials, market forces, and environmental 
factors are core criteria for company research priority setting.  Given the complex nature 
of research priority setting, BoD is not a sole criterion that companies use, although it is 
important to them because BoD is linked to feasibility, market, and environmental 
factors. For example, the higher the BoD, the greater number of potential participants 
make trials more feasible, the larger number of prospective consumers make sales 
forecasts more appealing, and the greater sense of urgency to resolve a high BoD may 
make for an environment more supportive of research. 
 
The degree of association between pharmaceutical company research and the country’s 
BoD depends on which measure of research is compared (company or trial priority, 
number of participants or sites planned and final), which BoD measure is used (Death, 
YLLs, DALYs) and which comparative statistic is applied (Spearman’s rank correlations 
or correlations and regressions with actual values).  This analysis revealed the 
complexities of comparing research to BoD and the importance of examining multiple 
measures of both research and BoD because investigating only one measure could be 
misleading.   
 
The results suggest that companies’ actions in South Africa – evidenced by the number 
of participants they have in trials – are more in line with the country’s BoD than the 
companies’ stated priorities. Across both Pearson and Spearman rank correlations for all 
measures of research and BoD, the strongest association between pharmaceutical 
company research and South Africa’s BoD is for participants planned, whereas the 
weakest association is for company stated priorities.  No substantial difference for 
correlations is apparent when HIV/AIDS is excluded.  Furthermore, across the same 
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correlations there is clearly a stronger association with Deaths, than for YLLs or DALYs.    
One interpretation of this might be that mortality data are more readily available and 
therefore used in priority setting.  Research may be less in line with YLLs and DALYs 
because these composite measures are relatively new, not available or known. 
 
When BoD is used as the sole comparator in regression analysis between 
pharmaceutical company research and South Africa’s BoD, an abundance of research is 
found in cardiovascular disease, mental disorders and musculo-skeletal disease.  
Opportunities for more research are in benign neoplasms, maternal conditions, oral 
conditions, and perinatal diseases.  Pharmaceutical company research in and near 
alignment with South Africa’s BoD is in HIV/AIDS, infectious and parasitic diseases 
(excluding HIV/AIDS), nervous system disorders, and skin disorders. 
 
When only BoD is used as a criterion, one conclusion is that less research should be 
devoted to the areas with an abundance of research, more research should be 
concentrated on areas with opportunities for more research, and just the right amount of 
research is being conducted in areas in alignment with the country’s BoD.  Or, as the 
qualitative results from this study suggest, another conclusion is that priority setting is 
more complex and encompasses more than BoD as a criterion.  The abundance of 
research may be because companies not only currently find trials feasible, and the 
market and environment conducive, but perhaps they anticipate the future to be even 
more encouraging.  For those areas that are in need of more research, companies may 
not find the research feasible, or the market or environment supportive.  For those 
diseases in alignment, companies may find that the current feasibility, market and 
environment for trials is such that they are encouraged to conduct research in areas that 
happen to reflect the country’s BoD. 
 
This study also reveals five core issues that merit further investigation.  First, this study 
does show that feasibility, market and environmental factors are all important in a 
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company’s decision-making process to conduct research; however, the relative weight of 
these facilitating and constraining factors is unknown.  For example, the relative 
importance of how many patients are available, what the timeline is for regulatory 
approval of the clinical trial, what the market potential is, and the overall cost of the trial 
has not been established.  Better knowledge of these dynamics will enable the creation 
of more appropriate incentives to encourage research in diseases of need.  Secondly, it 
is not well-substantiated how South Africa compares with other countries with regard to 
its overall research environment.  For example, Eastern Europe was often raised as a 
competitor to South Africa for attracting research, but it was unclear why specifically.  A 
better understanding of South Africa’s international position would enable the creation of 
strategies not only in relation to what can be done to encourage research in South 
Africa, but also what can be improved in comparison with other countries.  Thirdly, it is 
not known how much additional research conducted outside of the country South 
Africans benefit from and how this relates to the country’s burden of disease.  Many 
international trials are already conducted in the country, and this study revealed the 
majority of South African trials were for products that were either registered or planning 
on being registered in the country.  Therefore, it would be interesting to explore how 
many products have been registered based on trials conducted outside of the country.  
Fourthly, a better understanding of the relationship between local and global company 
headquarters would reveal another angle to companies’ priority setting process.  For 
example, to assess whether or not global priorities differ from local affiliates, and if so in 
what way, and whether the local office has enough funds to conduct trials on its own 
could perhaps lead to additional strategies that would impact companies both at the local 
and global levels.  Lastly, and most importantly for pharmaceutical research with human 
participants, it is essential to further examine ways to ensure that the ethics, quality, and 
integrity of research is incorporated into any strategy which seeks to encourage more 
research in areas of need.  This will not only protect participants, investigators, the 
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public, and sponsors of research, it will foster a better overall environment for 
pharmaceutical research. 
 
In conclusion, this study fulfils the need for a “detailed audit of … health research in 
[South Africa]” (Schneider 2001, iv) with respect to the private pharmaceutical industry 
by establishing a baseline understanding of where company research in South Africa is 
currently focused in relation to the country’s BoD.  Furthermore, this study reveals the 
complex nature of pharmaceutical company research priority setting.  It can, therefore, 
inform public and private industry policy makers to identify practical strategies to 
encourage company research in diseases of need so that private pharmaceutical 
industry research can be maximised to benefit public health. 
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Appendix 1: Pharmaceutical Company Questionnaire 
 
Company Contact Information – Part I   
(for administrative purposes only) 
 
1. Name 
 
      
2. Title 
 
      
3. Name of Person(s) 
Completing the 
Questionnaire  
(if different from you) 
      
4. Company Name 
 
      
Postal Address  
       5. Street/Private Bag 
 
      
       6. City 
 
      
       7. Code 
 
      
Physical Address  
       8. Street 
 
      
       9. City 
 
      
       10. Code 
 
      
11. Telephone (office) 
 
      
12. Telephone (cell) 
 
      
13. Fax 
 
      
14. Email 
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Questionnaire – Part II 
 
 
1.  Please select the top 5 general disease categories in order of priority where your 
company focuses its clinical trial research in South Africa. 
 
 
1.1 Priority #1 
Please click on the shaded box to select a category: 
Drop down box appeared with list of MRC disease 
categories and respective codes for participant to select one 
1.2 Priority #2 
Please click on the shaded box to select a category: 
Drop down box  (ignore if “X” in None) 
 
None  
1.3 Priority #3 
Please click on the shaded box to select a category: 
Drop down box  (ignore if “X” in None) 
 
None  
1.4 Priority #4 
Please click on the shaded box to select a category: 
Drop down box  (ignore if “X” in None) 
 
None  
1.5 Priority #5 
Please click on the shaded box to select a category: 
Drop down box  (ignore if “X” in None) 
 
None  
2.  In which country is your company headquarters? 
Please name 
      
3.  Did you conduct pre-clinical research at any time during 
2000, 2001, 2002 or 2003 in South Africa? Yes  (1) No  (2) 
4.  Do you currently have people in your company whose 
primary responsibility is to conduct or manage clinical trials in 
South Africa? 
Yes  (1) No  (2) 
5.  If yes to Question 4, how many people in your company 
have responsibility for conducting or managing clinical trial 
research in South Africa? 
Please enter the number  
 
      people 
6. Please feel free to make any additional comments or explanations in the space 
provided below.   
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Questionnaire – Part III          
Clinical Trial # 1 (one page per trial) 
7. In what year did this trial receive 
South African Ethics Committee 
A l?
2000  (0) 2001  (1) 2002  (2) 
2003  
(3) 
8.  What is the specific DISEASE TARGET this trial seeks to address? 
Please type/write in the specific TARGET and its respective CODE from the attached file “Disease 
List.doc” 
 
(If more than one target, please list in order of priority.  Please note this question is more specific than the general DISEASE 
8.1 Priority Disease Target # 1 (e.g., COPD) 
        
(If other, please specify      ) 
Code 
       (e.g., 88) 
8.2 Priority Disease Target #2                    
                                            
(If other, please specify      )     or  None  
Code 
      
9. What Phase is this trial?  
Please refer to South African Department of Health Definitions in “Intro & Instructions.doc” and check only one box. Note all 
included trials must have Ethics Committee approval. 
Phase One  (1) Phase Two  (2) Phase Three  (3) Phase Four  (4) 
10.  What is the total number of participants (patients) planned at 
time of Ethics Committee approval for this trial in South Africa? 
Please enter the number 
      planned participants 
11.  What is the total number of enrolled participants (patients 
who signed informed consent) by 1 January 2004 for this trial in 
South Africa? 
Please enter the #  (can be “0”) 
      enrolled participants 
12.  What is the total number of planned sites in South Africa with 
a registered Principal Investigator for this trial? 
Please enter the number 
      planned sites 
13.  What is the total number of final sites in South Africa by 1 
January 2004 with a registered Principal Investigator for this trial?  
Please enter the #  (can be “0”) 
      final sites 
14. Is this trial for prevention and/or 
treatment? 
(P ti i d )
Preventio
n only  
(1)
Treatment 
only  (2) 
Prevention  AND 
treatment  (3) 
15.  Is this part of a multi-country clinical trial? Yes  (1) No  (2) 
16.  Will you seek registration of this 
investigational product (or new 
indication, dosage, strength, etc.)  in 
South Africa? 
Yes  
(1) 
No  
(2) 
Already  
registered  (3) 
Don’t know 
 (4) 
17.  Is this a South-African investigator-initiated trial? Yes  (1) No  (2) 
18.  Is yes to #17, is this trial also approved by your headquarters 
(if you are an international company)? Yes  (1) No  (2) 
19. Did either you or your Headquarters contract out any portion of 
this clinical trial in South Africa at any time?  Yes  (1) No  (2) 
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Appendix 2: Pharmaceutical Semi-structured Interview Questions 
 
 
1.  Please tell me about the process for how your company decides to conduct 
clinical trials in South Africa. 
 
     Prompts: Who is involved? How long does decision-making take? 
 
 
 
2.  What issues or factors does your company consider when deciding to conduct 
clinical trials in South Africa? 
 
 Prompts: Facilitating factors? Constraining factors? What about disease burden? 
 
 
 
3.  Why does your company prioritise the disease categories for research in South 
Africa in the way that they have? 
 
Prompts: What are the criteria, conditions, circumstances, facilitating or 
constraining factors? 
 
 
 
4. Any other comments? 
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Appendix 3: Disease Categories and Codes 
Disease Category 
Disease Target 
Code 
  
Cardiovascular  M 
Aortic aneurism 85 
Cardiomyopathy 81.2 
Hypertensive heart disease 82 
Inflammatory heart disease 81 
Ischaemic heart disease 79 
Non-rheumatic valvular disease 83 
Peripheral vascular disorders 86 
Peri-, endo, myocarditis 81.1 
Pulmonary embolism 84 
Rheumatic heart disease 78 
Stroke 80 
Other cardiovascular 87 
  
Respiratory diseases  N 
Aspiration pneumonia/ lung abscess 90 
Asthma 89 
COPD 88 
Other respiratory 91 
  
Respiratory infections  B 
Otitis media 16 
Lower respiratory infections 14 
Upper respiratory infections 15 
  
Digestive  O 
Appendicitis 94 
Cirrhosis of liver 93 
Gall bladder disease 96 
Intestinal obstruction, non-infective gastroenteritis and colitis, peritonitis 95 
Pancreatitis 97 
Peptic ulcer 92 
Other digestive 98 
  
Genito-urinary  P 
Benign prostatic hypertrophy 100 
Nephritis/nephrosis 99 
Stress incontinence 101 
Other genito-urinary 102 
  
Musculo-skeletal  R 
Osteoarthritis 105 
Rheumatoid arthritis 104 
Other musculo-skeletal 106 
  
 --
--
--
 D
is
ea
se
 T
ar
ge
ts
 --
--
--
- 
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Nervous system disorders  K 
Alzheimer and other dementias 68 
Encephalitis and brain abscess 72 
Epilepsy 71 
Multiple sclerosis 70 
Parkinsons disease 69 
Other nervous system disorders 73 
  
Skin disease Q 
 Skin disease 103  
  
Sense organs  L 
Cataracts 75 
Glaucoma 74 
Hearing loss and other ear disorders 77 
Other visual disorders 76 
  
Infectious and parasitic A 
Bacterial meningitis 6 
Childhood (Vaccine preventable) cluster 5 
Diarrhoeal diseases 4 
Diptheria 5.3 
Hepatitis 7 
Intestinal parasites 11 
Leprosy 10 
Malaria 8 
Measles 5.4 
Pertussis 5.1 
Polio 5.2 
Rubella 5.6 
Schistosomiasis and other tropical diseases 9 
Septicaemia 12 
STDs excluding HIV 2 
Other STDs 2.2 
Syphilis 2.1 
Tetanus 5.5 
Tuberculosis 1 
Other infectious and parasitic 13 
    
HIV/AIDS  X 
Acquired immunity deficiency syndrome 3 
  
Malignant neoplasms  F 
Bladder 48 
Bone and connective tissue 40 
Brain 50 
Breast 43 
Cervix 44 
Colo-rectal 35 
Corpus uteri 45 
Kidney 49 
Larynx 38 
Leukaemia 52 
Liver 36 
Lymphoma 51 
Melanoma 41 
Mouth and oropharynx 32 
Oesophagus 33 
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Ovary 46 
Pancreas 37 
Prostate 47 
Stomach 34 
Trachea/bronchi/lung 39 
Other skin cancer 42 
Other malignant neoplasms 53 
  
Benign neoplasms G 
 Benign neoplasms 54  
  
Diabetes mellitus H 
Diabetes mellitus 55 
    
Endocrine and metabolic disorders  I 
Albinism 56 
Other endocrine and metabolic 57 
    
Mental disorders  J 
Adjustment reaction (PTSS) 65 
Affective disorders  (depression, bipolar) 61 
Alcohol dependence 58 
Anorexia nervosa 62 
Anxiety disorders (Obsessive compulsive/ panic disorders)  63 
Drug use 59 
Hyperkinetic Syndrome of childhood 64 
Mental disability 66 
Schizophrenia 60 
Other mental disorders 67 
    
Maternal conditions  C 
Abortion 21 
Hypertension in pregnancy 19 
Maternal haemorrhage 17 
Maternal sepsis 18 
Obstructed labour 20 
Other maternal 22 
    
Perinatal conditions  D 
Birth asphyxia and trauma 24 
Foetal alcohol syndrome 27 
Low birth weight 23 
Neonatal infections 26 
Other respiratory conditions 25 
Other perinatal 28 
    
Nutritional deficiencies  E 
Deficiency anaemias 30 
Protein-energy malnutrition 29 
Other nutritional deficiencies including pellagra and vitamin A deficiency 31 
    
Congenital abnormalities  S 
Cleft lip/palate 108 
Congenital disorders of GIT 110 
Congenital heart disease 109 
Down’s syndrome and other chromosomal anomalies 111 
Neural tube defects 107 
Other congenital abnormalities 112 
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Cot death  U 
Cot death  116 
    
Oral conditions  T 
Dental caries 113 
Periodontal disease 114 
Other oral health 115 
    
Unintentional injuries  V 
Drowning 125 
Falls 122 
Fires 123 
Mining accidents 119 
Natural and environmental factors 124 
Other transport accidents 118 
Poisoning 120 
Road traffic accidents 117 
Suffocation and foreign bodies 126 
Surgical / medical misadventure 121 
Other unintentional injuries specified 127 
    
Intentional injuries  W 
Legal intervention and war 130 
Homicide and violence 129 
with firearm 129.1 
without firearm 129.2 
Suicide and self-inflicted 128 
    
 OTHER  Y 
Please do not choose this option unless you are unable to locate the relevant target from the list 
above.  This category is ONLY for those targets which are not included in the list above, (e.g., pain, 
smoking cessation, anaesthetics, allopecia, etc) 
 1000 
 
Source: Adapted with permission from Bradshaw D, Groenwald P, Laubscher R, Nannan N, Nojilana B, Norman R, 
Pieterse D and Schneider M (2003) Initial Burden of Disease Estimates for South Africa, 2000. Cape Town: South African 
Medical Research Council. 
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*Respiratory infections for participants enrolled considered an outlier
Appendix 4: Participants Planned and Enrolled, Sites Planned and Final per Disease 
Category 
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Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
16
16
16
16
Disease
# of 
Participants 
Enrolled
% of Total 
Participants 
Enrolled Rank Disease
# of Sites 
Planned
% of Sites 
Planned Rank Disease
# of Sites 
Final
% of Sites 
Final
Respiratory infections 8932 38.50% 1 Cardiovascular disease 666 40.36% 1 Cardiovascular disease 653 38.34%
Cardiovascular disease 4611 19.88% 2 Respiratory infections 160 9.70% 2 Genito-urinary diseases 174 10.22%
Musculo-skeletal diseases 1792 7.72% 3 Musculo-skeletal diseases 123 7.45% 3 Respiratory infections 155 9.10%
Respiratory disease 1328 5.72% 4 Respiratory disease 112 6.79% 4 Respiratory disease 115 6.75%
HIV/AIDS 1287 5.55% 5 Malignant neoplasms 108 6.55% 5 Malignant neoplasms 107 6.28%
Genito-urinary diseases 955 4.12% 6 Mental disorders 93 5.64% 6 Musculo-skeletal diseases 97 5.70%
Infectious/parasitic (ex HIV/AIDS) 778 3.35% 7 Digestive system diseases 83 5.03% 7 Mental disorders 89 5.23%
Mental disorders 756 3.26% 8 Genito-urinary diseases 63 3.82% 8 Digestive system diseases 74 4.35%
Diabetes mellitus 750 3.23% 9 HIV/AIDS 55 3.33% 9 HIV/AIDS 54 3.17%
Digestive system diseases 504 2.17% 10 Infectious/parasitic (ex HIV/AIDS) 51 3.09% 10 Nervous system disorders 47 2.76%
Malignant neoplasms 472 2.03% 11 Nervous system disorders 47 2.85% 11 Diabetes mellitus 43 2.52%
Nervous system disorders 388 1.67% 12 Diabetes mellitus 43 2.61% 12 Infectious/parasitic (ex HIV/AIDS) 38 2.23%
Endocrine and metabolic 312 1.34% 13 Endocrine and metabolic 28 1.70% 13 Endocrine and metabolic 31 1.82%
Other 278 1.20% 14 Other 12 0.73% 14 Other 14 0.82%
Skin diseases 57 0.25% 15 Skin diseases 6 0.36% 15 Sense organs 6 0.35%
Maternal conditions 0 0.00% 16 Maternal conditions 0 0.00% 15 Skin diseases 6 0.35%
Perinatal conditions 0 0.00% 16 Perinatal conditions 0 0.00% 17 Maternal conditions 0 0.00%
Benign neoplasms 0 0.00% 16 Benign neoplasms 0 0.00% 17 Perinatal conditions 0 0.00%
Sense organs 0 0.00% 16 Sense organs 0 0.00% 17 Benign neoplasms 0 0.00%
Oral conditions 0 0.00% 16 Oral conditions 0 0.00% 17 Oral conditions 0 0.00%
Sites Planned Priorities Sites Final PrioritiesParticipants Enrolled Priorities
Appendix 5: Participants Enrolled, Sites Planned, and Sites Final Numbers and Rankings per Disease Category 
(See Table 1 of report for Company, Trial and Participants Planned Numbers and Rankings per Disease Category) 
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Appendix 6: Regression Calculations Across All Measures 
Measure Regression 
slope
Regression slope 
confidence 
interval
Regression 
p-value 
(same as 
Pearson)
Companies vs. Deaths 0.09 -0.0058 - 0.1854 0.06
Companies vs. YLLs 0.07 -0.0073 - 0.1500 0.07
Companies vs. DALYs 0.13 -0.0832 - 0.3420 0.22
Trials vs. Deaths 0.20 -0.0400 - 0.3559 0.02
Trials vs. YLLs 0.14 0.0104 - 0.2791 0.04
Trials vs. DALYs 0.40 0.0619 - 0.7358 0.02
Participants planned vs. Deaths 0.57 0.1945 - 0.9481 0.01
Participants planned vs. YLLs 0.44 0.1269 - 0.7608 0.01
Participants planned vs. DALYs 0.89 0.0037 - 1.7849 0.05
Participants enrolled vs. Deaths 0.57 0.1836 - 0.9580 0.01
Participants enrolled vs. YLLs 0.45 0.1213 - 0.7701 0.01
Participants enrolled vs. DALYs 0.89 -0.0252 - 1.7982 0.06
Sites planned vs. Deaths 0.38 0.1296 - 0.6347 0.01
Sites planned vs. YLLs 0.29 0.0782 - 0.5064 0.01
Sites planned vs. DALYs 0.62 0.0238 - 1.2078 0.04
Sites final vs. Deaths 0.32 0.0583 - 0.5740 0.02
Sites final vs. YLLs 0.23  0.0121 - 0.4501 0.04
Sites final vs. DALYs 0.60  0.0410 - 1.1614 0.04
BOLD statistically significant
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Appendix 7: Regression Graphs for Measures with Pearson and Spearman p < 0,05 
 
(Please see Appendix 3 for legend with disease categories and codes) 
 
Graphs: Pearson’s p-value Spearman’s p-value 
Trials vs. Deaths 0,02 0,02 
Participants Planned vs. Deaths 0,01 0,01 
Participants Planned vs. YLLs 0,01 0,03 
Participants Planned vs. DALYs 0,05 0,05 
Participants Enrolled vs. Deaths 0,01 0,02 
Participants Enrolled vs. YLLs 0,01 0,03 
Sites Planned vs. Deaths 0,01 0,03 
Sites Planned vs. YLLs 0,01 0,05 
Sites Final vs. Deaths 0,02 0,04 
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